PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 1Title Page
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 
PARALLEL GROUP, DOSE RANGING STUDY TO EVALUATE VIROLOGICAL 
RESPONSE AND SAFETY OF ORAL PF-07817883 IN NON-HOSPI[INVESTIGATOR_837507]-19
Study Intervention Number: PF-07817883
Study Intervention Name: [CONTACT_336280]: [ADDRESS_1163148] Number: NA
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number: NA
Protocol Number: C5091003
Phase: 2B
Sponsor Legal Address: [COMPANY_007] Inc.
[ADDRESS_1163149] East[LOCATION_001], NY [ZIP_CODE]
Brief Title:
A Phase 2B Study To Evaluate Virological Response and Safety of Oral PF-07817883 in 
Non-Hospi[INVESTIGATOR_057], Symptomatic, Adult Participants With COVID-19.
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except 
as otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) 
or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be promptly notified.
090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163150] of country health authorities and IRBs/ECs and any protocol administrative change letter(s).
Protocol Amendment Summary of Changes Table
Amendment 2 (14 April 2023)Overall Rationale for the Amendment: To incorporate regulatory feedback on study 
population eligibility criteria.
Description of Change Brief Rationale Section # and Name
[CONTACT_185628](s)
Removed inclusion 
criterion #5, and updated inclusion criterion #2 and exclusion criterion #2 to prohibit enrollment of participants at high risk of progression to severe disease into this study.To address comments received from the FDA.Section 1.1 Synopsis, Section 5.1 Inclusion Criteria and Section 5.2 Exclusion Criteria
Edited text to remove reference to participants at high risk of progression to severe disease.To address comments received from the FDA.Section 1.1 Synopsis (Ethical Considerations and Exclusion Criterion #12), Section 2.3.2 Benefit Assessment, Section 5.2 Exclusion Criteria and Section 6.9 Prior and Concomitant Therapy.
Added Safety Laboratory Assessments for Blood and Urine at the Day 10visit.To address comments received from the FDA.Section 1.3 SoA
Removed collection ofretained research sample To reduce patient and operational burden by [CONTACT_8985] 1.3 SoA, Section 8.6.2 Retained Research Samples for 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 3Description of Change Brief Rationale Section # and Name
[CONTACT_837558] (Prep D1) at 
Day 3, Day 5 and ET visits. Clarified thatcollection of retained research sample for genetics (Prep D1) and retained research samples for biomarkers (Prep B2.5/R1) is optional.removing redundant samples (Days 3 and 5 and ET visits) and to address comments received from FDA (change retained research samples from mandatory to optional collections).Genetics and Section 8.7.6 Retained Research Samples for Biomarkers
Removed Sensitive CYP3A4 Substrates with Narrow Therapeutic Indexfor alignment withSection 6.9 Prior and Concomitant Therapy.To address comments received from the FDA.Section 10.9 Appendix 9:Prohibited Concomitant Medications That May Result in DDI
Removed the sponsors definition of viral RNA rebound.To address comments received from the FDA.Section 10.11 Appendix 11: Definition of Viral RNA Rebound
Deleted “or other trial involving PF-07817883” from exclusion criterion #15.To allow healthy participants from study C5091001 to enroll in this study if they develop COVID-19 at a later date.Section 1.1 Synopsis and Section 5.2 Exclusion Criteria
Added discontinuation criteria for participants who develop AKI.To comply with new updated guidance on theevaluation of potentialacute kidney injury.Section 7.1.1 Potential Cases of Acute Kidney Injury
Removed the option for home health visits.Home health visits were underutilized in previous studies.Section 1.1 Synopsis, Section 1.3 SoA, Section 4.1 Overall Design, Section 8.1.3 Home Health Visits and Section 8.3.3 Targeted Physical Examinations
Added additional reflex laboratory tests for DIKI in the right column of the table. Added laboratory tests for calculating UACR under “Urinalysis” column.To comply with new updated guidance on evaluation of potential acute kidney injury.Section 10.2 Appendix 2: Clinical Laboratory Tests090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 4Description of Change Brief Rationale Section # and Name
[CONTACT_51584]-substantial Modification(s)
Edited Study Visit 
Location notes to specify that Day [ADDRESS_1163151] be an in-person visit at the site.Section 1.3 SoA and Section 8.1.2 Telehealth Visits
Added text to specify that SARS-CoV-2 serology is a part of Other Laboratory Assessment and only Day 1 and Day 10 sample will be assessed for SARS-CoV-2 serology.Clarification that SARS-CoV-2 serology is evaluated with only Day 1and Day 10 sample.Section 1.3 SoA and Section 10.2 Appendix 2: Clinical Laboratory Tests
Edited “through Day 28” to “over time” for the first two tertiary/exploratory endpoints listed. To better align with SAP reporting and SoA.Section 3 Objectives, Endpoints, and Estimands
Added reference to viral RNA level assessment at Day 5.Provide consistency with Section 1.1 Synopsis –Statistical Methods.Section 4.1 Overall Design
Removed reference to receiving dialysis for exclusion criterion #7.Removed duplication since Chronic Kidney Disease requiring dialysis is already included in exclusion criterion #2.Section 5.2 Exclusion Criteria
Edited total blood sampling volume.To account for the Safety Laboratory Assessments added for Day 10 and the optional Day 21 retained research sample collection.Section 8.1 Administrative and Baseline Procedures
Added a sentence to clarify the investigator will determine whether medical visits are considered COVID-19-related.To address comments received from the FDA.Section 8.2.2 COVID-19-Related Medical Visit Details
Removed collection of 
previous mAb treatment CRF will not require that all
previous mAb Section 8.3.1 Medical History090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 5Description of Change Brief Rationale Section # and Name
[CONTACT_837559].treatment prior to the planned first dose of study drug be documented.
Addition of a sentence on reporting plan for exploratory endpoints.Clarification that some exploratory endpoints may not be reported in the CSR.Section 9.3.4 Tertiary/Exploratory Endpoint(s) Analysis
Added “(urine)” to Albumin Urinalysis assessment.Clarification that albumin assessment should be from a urine sample.Section 10.2 Appendix 2: Clinical Laboratory Tests
Edited interim analysis plan specifications and blinding plan.Clarifications on the planned protocol analysis.Section 9.[ADDRESS_1163152] number. ClinicalTrials.gov ID now 
available.Title Page
Moved Amendment 1 Summary of Change text and table into new Appendix 12.To comply with new regulatory requirements.Section 10.12 Appendix 12: Protocol Amendment History
Minor edits to clarify protocol text and correct minor errors and typos from previous versions.To clarify protocol text and correct inadvertent errors.Several sections throughout.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163153] OF TABLES................................................................................................................. ..12
1. PROTOCOL  SUMMARY...................................................................................................13
1.1. Synopsis .................................................................................................................. 13
1.2. Schema .................................................................................................................... 22
1.3. Schedule of Activities .............................................................................................23
2. INTRODUCTION ...............................................................................................................3 2
2.1. Study Rationale .......................................................................................................32
2.2. Background .............................................................................................................32
2.2.1. Nonclinical Studies of PF-07817883..........................................................322.2.2. Clinical Overview.......................................................................................33
[IP_ADDRESS]. Safety Overview........................................................................34
[IP_ADDRESS]. Summary of PF-07817883 Pharmacokinetics in Humans ........34
2.3. Benefit/Risk Assessment.........................................................................................36
2.3.1. Risk Assessment .........................................................................................372.3.2. Benefit Assessment.....................................................................................382.3.3. Overall Benefit/Risk Conclusion................................................................[ADDRESS_1163154] udy Population ....................................................................41
4.2.2. Choice of Contraception/Barrier Requirements .........................................424.2.3. Collection of Retained Research Samples..................................................42
4.3. Justification for Dose ..............................................................................................424.4. End of Study Definition ..........................................................................................43
5. STUDY POPULATION ......................................................................................................43
5.1. Inclusion Criteria.....................................................................................................43
5.2. Exclusion Criteria....................................................................................................445.3. Lifestyle Cons iderations..........................................................................................47
5.3.1. Contraception..............................................................................................47090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 75.4. Screen Failures ........................................................................................................48
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY .................................48
6.1. Study Intervention(s) Administered ........................................................................48
6.1.1. Administration ............................................................................................50
6.2. Preparation, Handling, Storage, and Accountability...............................................50
6.2.1. Preparation and Dispensing ........................................................................51
6.3. Assignment to Study Intervention...........................................................................51
6.4. Blinding...................................................................................................................52
6.4.1. Blinding of Participants ..............................................................................526.4.2. Blinding of Site Personnel..........................................................................526.4.3. Blinding of the Sponsor..............................................................................526.4.4. Breaking the Blind......................................................................................52
6.5. Study Intervention Compliance...............................................................................536.6. Dose Modification...................................................................................................536.7. Continued Access to Study Intervention After the End of the Study......................546.8. Treatment of Overdose............................................................................................546.9. Prior and Concomitant Therapy ..............................................................................54
6.9.1. Rescue Medicine.........................................................................................55
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL...........................................................................56
7.1. Discontinuation of Study Intervention ....................................................................56
7.1.1. Potential Cases of Acute Kidney Injury .....................................................577.1.2. Liver Injury.................................................................................................587.1.3. ECG Changes..............................................................................................58
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_1163155] to Follow-Up ...................................................................................................59
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................59
8.1. Administrative and Baseline Procedures.................................................................59
8.1.1. Secondary Contacts ....................................................................................608.1.2. Telehealth Visits .........................................................................................61
8.2. Efficacy Assessments..............................................................................................61090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 88.2.1. Participant Diary.........................................................................................61
8.2.2. COVID-19-Related Medical Visit Details..................................................628.2.3. Daily Signs and Symptoms of COVID-19 .................................................628.2.4. Oxygen Support Details..............................................................................638.2.5. Global Impression Questions......................................................................63
8.3. Safety Assessments .................................................................................................63
8.3.1. Medical History ..........................................................................................648.3.2. Height and Weight......................................................................................648.3.3. Targeted Physical Examinations.................................................................648.3.4. Vital Signs ..................................................................................................64
[IP_ADDRESS]. Blood Pressure and Pulse Rate..................................................[IP_ADDRESS]. Temperature and Respi[INVESTIGATOR_13581]............................................[IP_ADDRESS]. Oxygen Saturation Level...........................................................65
8.3.5. Electrocardiograms.....................................................................................658.3.6. Clinical Safety La boratory Asse ssments ....................................................66
[IP_ADDRESS]. Alternative Facilities for Clinical Safety Laboratory 
Assessment ........................................................................................66
8.3.7. Pregnancy Testing ......................................................................................66
[IP_ADDRESS]. At-Home Pregnancy Testing.....................................................[IP_ADDRESS]. Evaluation for Menopause ........................................................67
8.3.8. Adjunctive Therapeutic Procedures............................................................67
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................67
8.4.1. Time Period and Frequency for Collecting AE and SAE Information.......68
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................69
8.4.2. Method of Detecting AEs and SAEs ..........................................................698.4.3. Follow-Up of AEs and SAEs......................................................................698.4.4. Regulatory Reporting Requirements for SAEs...........................................698.4.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................70
[IP_ADDRESS]. Exposure During Pregnancy......................................................70
[IP_ADDRESS]. Exposure During Breastfeeding ................................................72090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page [IP_ADDRESS]. Occupational Exposure .............................................................72
8.4.6. Cardiovascular and Death Events...............................................................72
8.4.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_1163156].............................................................72
[IP_ADDRESS]. Lack of Efficacy........................................................................73
8.4.9. Medical Device Deficiencies......................................................................738.4.10. Medication Errors .....................................................................................73
8.5. Pharmacokinetics ....................................................................................................748.6. Genetics.................................................................................................................. .75
8.6.1. Specified Genetics ......................................................................................758.6.2. Retained Research Samples for Genetics ...................................................75
8.7. Biomarkers ..............................................................................................................75
8.7.1. Rapid Antigen Assessments .......................................................................768.7.2. Specified Gene Expression (RNA) Research .............................................768.7.3. Specified Protein Research .........................................................................768.7.4. Specified Metabolomic Research ...............................................................768.7.5. Viral RNA Level Assessments ...................................................................768.7.6. Retained Research Samples for Biomarkers...............................................77
8.8. Immunogenicity Assessments .................................................................................778.9. Health Economics ...................................................................................................77
9. STATISTICAL C ONSIDERATIONS ................................................................................77
9.1. Statistical Hypothesis ..............................................................................................77
9.1.1. Estimands....................................................................................................78
[IP_ADDRESS]. Primary Estimand......................................................................[IP_ADDRESS]. Secondary Estimands ................................................................78
9.1.2. Multiplicity Ad justment..............................................................................78
9.2. Analysis Sets ...........................................................................................................789.3. Statistical Analyses .................................................................................................79
9.3.1. General Considerations...............................................................................799.3.2. Primary Endpoint(s)/Estimand(s) Analysis ................................................80
[IP_ADDRESS]. Definition of Endpoint(s) ..........................................................80090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page [IP_ADDRESS]. Main Analytical Approach ........................................................80
[IP_ADDRESS]. Supplementary Analyses ...........................................................81
9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis ............................................819.3.4. Tertiary/Exploratory Endpoint(s) Analysis ................................................819.3.5. Other Safety Analyses ................................................................................81
[IP_ADDRESS]. Electrocardiogram Analyses......................................................81
9.3.6. Other Analyses............................................................................................81
9.4. Interim Analyses .....................................................................................................829.5. Sample Size Determination.....................................................................................829.6. Analysis of Pharmacokinetic Endpoints .................................................................83
9.6.1. Early PK/PD Unblinding Plan....................................................................83
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................84
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............84
10.1.1. Regulatory and Ethical Considerations ....................................................84
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................84
10.1.2. Financial Disclosure .................................................................................8510.1.3. Informed Consent Process ........................................................................8510.1.4. Data Protection .........................................................................................8610.1.5. Committees Structure ...............................................................................86
[IP_ADDRESS]. Data Monitoring Committee ...................................................86
10.1.6. Dissemination of Clinical Study Data ......................................................8710.1.7. Data Qualit y Assurance ............................................................................88
10.1.8. Source Documents....................................................................................8910.1.9. Study and Site Start and Closure ..............................................................9010.1.10. Publication Policy...................................................................................9010.1.11. Sponsor’s Medically Qualified Individual..............................................91
10.2. Appendix 2: Clinical Laboratory Tests .................................................................9210.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................93
10.3.1. Definition of AE .......................................................................................93090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 1110.3.2. Definition of an SAE ................................................................................94
10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................96
10.3.4. Reporting of SAEs....................................................................................99
10.4. Appendix 4: Contraceptive and Barrier Guidance ..............................................100
10.4.1. Male Participant Reproductive Inclusion Criteria ..................................[ZIP_CODE].4.2. Female Participant Reproductive Inclusion Criteria...............................[ZIP_CODE].4.3. Woman of Childbearing Potential ..........................................................[ZIP_CODE].4.4. Contraception Methods...........................................................................102
10.5. Appendix 5: Genetics ..........................................................................................[ZIP_CODE].6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments 
and Study Intervention Rechallenge Guidelines .....................................................105
10.7. Appendix 7: Kidney Safety Monitoring Guidelines ...........................................107
10.7.1. Laboratory Assessment of Change in Kidney Function and 
Detection of Kidney Injury ............................................................................107
10.7.2. Age-Specific Kidney Function Calculation Recommendations.............107
[IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD-EPI 
[INVESTIGATOR_185560] .........................................................................................107
10.7.3. Adverse Event Grading for Kidney Safety Laboratory 
Abnormalities.................................................................................................107
10.8. Appendix 8: ECG Findings of Potential Clinical Concern .................................[ZIP_CODE].9. Appendix 9: Prohibited Concomitant Medications That May Result in DDI.....[ZIP_CODE].10. Appendix 10: Signs and Symptoms Attributable to COVID-19.......................[ZIP_CODE].11. Appendix 11: Definition of Viral RNA Rebound .............................................[ZIP_CODE].12. Appendix 12: Protocol Amendment History.....................................................[ZIP_CODE].13. Appendix 13: Abbreviations .............................................................................119
11. REFERENCES ................................................................................................................1 24090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163157] OF TABLES
Table 1. Study Schedule of Assessment .................................................................23
.....35
.....36
Table 4. Protocol Required Safety Laboratory Assessments..................................92
Table 5. Signs and Symptoms Attributable to COVID-19 ...................................112090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 131. PROTOCOL SUMMARY 
1.1. Synopsis Protocol Title: A Phase 2B, Double-Blind, Randomized, Placeb o-Controlled, Parallel Group, Dose Ranging 
Study to Evaluate Virological Response and Safety of Oral PF-07817883 in Non-
Hospi[INVESTIGATOR_057], Symptomatic, Adult Participants with COVID-19.
Brief Title:
A Phase 2B Virological Response and Safety Study of PF-07817883 in Non-Hospi[INVESTIGATOR_057],
Symptomatic, Adult Participants With COVID-19.
Regulatory Agency Identification Number(s):
US IND Number: [ADDRESS_1163158] Number: NA
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number: NA
Protocol Number: C5091003
Phase: 2B
Rationale:The purpose of this study is to assess the effect of PF-07817883 on severe acute respi[INVESTIGATOR_11520] 2 (SARS-CoV-2) ribonucleic acid (RNA) level reduction in nasopharyngeal (NP) samples and to evaluate the safety of PF-07817883 treatment in non-hospi[INVESTIGATOR_057], symptomatic, adult participants with coronavirus disease 2019 (COVID-19).The study is designed as a dose-ranging study to collect pharmacological and safety information to inform dose selection of PF-07817883 in later stage Phase 2/3 studies.
Objectives, Endpoints, and Estimands:
Objectives Endpoints Estimands
Primary: Primary: Primary: 
!To describe the effect of
PF-07817883 treatment versus 
placebo on SARS-CoV-2 RNA 
levels in NP samples in non-hospi[INVESTIGATOR_837508]-19.!Change from baseline in SARS-CoV-2 RNA level on Day 5.!E1: The estimand is the difference between the PF-[ADDRESS_1163159] 
SARS-CoV-2 RNA level 
≥4l o g
10copi[INVESTIGATOR_014]/mL at baseline. This 
analysis will exclude data after use of 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 14Objectives Endpoints Estimands
prohibited COVID-19 medications and 
after study treatment discontinuation.
Secondary: Secondary: Secondary: 
!To describe the effect of 
PF-07817883 treatment versus placebo on SARS-CoV-2 RNA
levels in NP samples in non-
hospi[INVESTIGATOR_837508]-19.!Change from baseline in SARS-CoV-2 RNA level on Days 3, 10 and 14.!E1: The estimand is the difference between the PF-[ADDRESS_1163160] 
SARS-CoV-2 RNA level 
≥4l o g
10copi[INVESTIGATOR_014]/mL at baseline. This 
analysis will exclude data after use of 
prohibited COVID-19 medications and after study treatment discontinuation.
!To describe the safety and tolerability of PF-07817883relative to placebo in the 
treatment of non- hospi[INVESTIGATOR_057], 
symptomatic, adult participants 
with COVID-19.!Incidence of treatment-emergent 
adverse events (TEAEs).
!Incidence of serious adverse 
events (SAEs) and adverse events 
(AEs) leading to discontinuations.
!Incidence of clinically significant 
abnormal laboratory values, vital 
signs, and electrocardiograms 
(ECGs).!Not applicable (NA).
Overall Design:
This is a Phase 2B, double-blind, randomized, placebo-controlled, parallel group, dose 
ranging study to assess the effect of PF-07817883 treatment on SARS-CoV-2 RNA level reduction in NP samples in non-hospi[INVESTIGATOR_057], symptomatic, adult participants with COVID-19. Approximately 228 eligible participants with a confirmed diagnosis of SARS-CoV-2 infection are planned to be randomized into the study to ensure approximately 180 participants with baseline SARS-CoV-2 RNA level ≥ 4 log
10copi[INVESTIGATOR_014]/mL complete the study. 
Participants will be randomized in a 1:1:2:2 ratio to receive PF-07817883 100, 300, or 600 mg, or placebo orally every 12 hours (q12h) for 5 days (10 doses total). Study visits should take place at the investigational site.
The total study duration is up to [ADDRESS_1163161] administration of the study intervention.
Number of Participants:Approximately 228 participants will be randomly assigned to study intervention to provide 
~180 completers with baseline SARS-CoV-2 RNA level ≥4 log
10copi[INVESTIGATOR_014]/mL.
Note: "Enrolled" means a participant's, or his or her legally authorized representative’s, agreement to participate in a clinical study following completion of the informed consent process and screening. A participant will be considered enrolled if the informed consent is 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 15not withdrawn prior to participating in any study activity after screening. Potential 
participants who are screened for the purpose of determining eligibility for the study, but do not participate in the study, are not considered enrolled, unless otherwise specified by [CONTACT_760]. 
Intervention Groups and Duration:Participants will be screened within 48 hours before randomization. Eligible participants will 
receive PF-07817883 (100, 300 or 600 mg) or placebo orally q12h for [ADDRESS_1163162] administration of the study intervention.
Data Monitoring Committee or Other Independent Oversight Committee: YesAn independent internal review committee (IRC) will review unblinded data to ensure the 
safety of participants throughout the duration of the study, as specified in the IRC Charter. In addition to safety reviews, the IRC will review the interim analysis.
Details of the IRC are specified in the IRC Charter.Study Population:Inclusion and exclusion criteria are listed below:Inclusion Criteria Participants must meet the following inclusion criteria to be eligible for enrollment into the 
study:
Age and Sex:
1. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.
2. Participants ≥18 to <65 years of age at the time of the Screening Visit.
!Woman/women of childbearing potential (WOCBP) may be enrolled.
!All fertile participants must agree to use a highly effective method of 
contraception.
Disease Characteristics:
3. Confirmed SARS-CoV-2 infection as determined by [CONTACT_837537] (RAT) in 
nasal specimen collected within 48 hours prior to randomization. Investigator sites 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163163] be 
available to confirm eligibility.
4. Initial onset of signs/symptoms attributable to COVID-[ADDRESS_1163164] 1 of the specified signs/symptoms attributable to COVID-19 present on the day of randomization.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded:
1. Current need for hospi[INVESTIGATOR_295361] 24h 
after randomization in the clinical opi[INVESTIGATOR_91382].
Medical conditions:
2. Has at least 1 characteristic or underlying medical condition (self-report is 
acceptable) associated with an increased risk of developi[INVESTIGATOR_837509]-19. The list of the characteristics or conditions includes:
!Body mass index (BMI) ≥30 kg/m
2;
!Current smoker (cigarette smoking within the past 30 days) and history of at least 
100 lifetime cigarettes;
!Chronic lung disease (ie, bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, pulmonary hypertension);
!Asthma, requiring daily prescribed therapy;
!Cardiac vascular disease, defined as history of any of the following: myocardial infarction, stroke, transient ischemic attack, heart failure, angina with prescribed nitroglycerin, coronary artery by[CONTACT_9292], percutaneous coronary intervention, carotid endarterectomy, and aortic by[CONTACT_6476];
!Type 1 or Type 2 diabetes mellitus;
!Chronic Kidney Disease requiring dialysis;
!Neurodevelopmental disorders (eg, cerebral palsy, Down’s syndrome) or other conditions that confer medical complexity (eg, genetic or metabolic syndromes and severe congenital anomalies);
!Active cancer other than localized skin cancer, including those requiring treatment (including palliative treatment), as long as the treatment is not among 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163165] be administered/continued during the trial 
period;
!Medical-related technological dependence (eg, CPAP [continuous positive airway pressure] [not related to COVID-19]).
3. Known medical history of active liver disease, including chronic or active hepatitis B 
or C infection, primary biliary cirrhosis, Child-Pugh Class B or Class C, or acute liver failure.
4. History of hypersensitivity or other contraindication to any of the components of the 
study interventions, as determined by [CONTACT_093].
5. Suspected or confirmed concurrent active systemic infection other than COVID-19 
that may interfere with the evaluation of response to the study intervention.
6. Immunocompromised with ≥1 of the following:
a. Solid organ (eg, liver, heart, lung or kidney) transplant recipi[INVESTIGATOR_837510].
b. Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic 
cell transplantation (HCT) either within 2 years of transplantation or receiving immunosuppressive therapy.
c. Moderate or severe primary immunodeficiency (eg, DiGeorge syndrome, 
Wiskott-Aldrich syndrome).
d. Use of at least 1 of the following immune-weakening medications:
i. Has received corticosteroids equivalent to prednisone ≥[ADDRESS_1163166] 14 consecutive days within 30 days prior to study entry.
ii. Active treatment causing significant immunosuppression, including 
alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents, tumor necrosis factor (TNF) blockers, or other highly immunosuppressive drugs such as biologics.
e. Hematological malignancy (including leukemia, lymphoma and myeloma) or 
active immunosuppressive treatment for solid tumor.
f. Human immunodeficiency virus (HIV) infection with CD4 cell count <[ADDRESS_1163167] 6 months of screening.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 187. Known severe renal impairment (estimated glomerular filtration rate [eGFR] of 
<30 mL/min/1.73 m2within 6 months of the screening visit, using the serum 
creatinine-based chronic kidney disease epi[INVESTIGATOR_623] [CKD-EPI] formula).
8. Oxygen saturation of <92% on room air obtained at rest within 24h prior to 
randomization.
a. NOTE: For a potential participant who regularly receives chronic 
supplementary oxygen for an underlying lung condition, oxygen saturation 
should be measured while on their standard home oxygen supplementation.
9. Any comorbidity requiring hospi[INVESTIGATOR_5478]/or surgery within 7 days prior to study 
entry, or that is considered life threatening within 30 days prior to study entry, as determined by [CONTACT_093].
10. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.
Prior Concomitant Therapy:
11. Current use of any prohibited concomitant medication(s).12. Use of any locally available oral or injectable antiviral medication intended to treat 
symptomatic SARS-CoV-2 infection before and at enrollment are excluded. After 
enrollment, locally available SARS-CoV-2 treatment (including but not limited to molnupi[INVESTIGATOR_42654], mAbs, outpatient IV remdesivir, convalescent plasma) will be permitted per investigator judgement. Note: PAXLOVID is contraindicated to be administered concurrently with the study intervention due to drug-drug interation(DDI) risk.
13. Expected to receive any dose of a SARS-CoV-2 vaccine within 14 days of 
randomization or during the study.
Prior/Concurrent Clinical Study Experience:
14. Current or previous administration with an investigational product (drug or vaccine) 
within 30 days (or as determined by [CONTACT_19970]) or [ADDRESS_1163168] dose of study intervention used in this study (whichever is longer). Authorized or products with conditional approval are not considered investigational.
15. Known prior participation in this trial.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 19Diagnostic Assessments:
16. Laboratory assessments not required at screening unless deemed necessary by [CONTACT_837538]. If deemed necessary, laboratory assessments at 
screening will be performed at local laboratory. The medical laboratory test abnormalities within [ADDRESS_1163169] be closely assessed. If abnormalities cannot be verified, consider conducting local laboratory testing at screening to confirm eligibility for the study .
17. Known history of any of the following abnormalities in clinical laboratory tests 
(within past 6 months of the screening visit):
!Total bilirubin (T bili) ≥2 × upper limit of normal (ULN) (except for Gilbert’s 
syndrome)
!Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5 ×
ULN
!Absolute neutrophil count <1000/mm
3.
18. Baseline standard 12-lead ECG that demonstrates clinically relevant abnormalities 
that may affect participant safety or interpretation of study results (eg, QTc corrected using Fridericia’s formula [QTcF] >450 ms, complete left bundle branch block(LBBB), signs of acute myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree atrioventricular (AV) block, or serious bradyarrhythmias or tachyarrhy thmias). If the baseline uncorrected QT interval is 
>450 ms, this interval should be rate corrected using the Fridericia method only and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 ms, or QRS exceeds 120 ms, the ECG should be repeated twice and the average of the 3 QTcF or QRS values used to determine the participant’s eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
Other Exclusion Criteria: 
19. Females who are pregnant or breastfeeding.
20. Investigator site staff directly involved in the conduct of the study and their family 
members, site staff otherwise supervised by [CONTACT_093], and sponsor and sponsor 
delegate employees directly involved in the conduct of the study and their family members.
Study Arms and Duration:
Eligible participants for this study will be randomly assigned (1:1:2:2) to receive 
PF-07817883 100, 300 or 600 mg, or placebo orally q12h as specified in the table below.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 20Study Intervention(s)
Intervention NamePF-07817883 PF-07817883 PF-07817883 Placebo for 
PF-07817883*
Arm Name
(group of 
participants receiving a specific treatment or no treatment)PF-07817883 100 mg q12hPF-07817883 300 mg q12hPF-07817883 600 mg q12hPlacebo
Unit Dose Strength(s)100 mg 300 mg 600 mg 0 mg
Route of AdministrationOral Oral oral Oral
Use Experimental experimental experimental Placebo
IMP or NIMP/AxMPI[INVESTIGATOR_837511]
* 2 tablet types for placebo to match with PF-07817883 100 mg and 300 mg, respectively.
AxMP=auxiliary medicinal product; IMP=investigational medicinal product; NIMP=noninvestigational medicinal 
product.
Study Arm(s)
Arm Title PF-07817883 
100 mg q12hPF-07817883 300 mg q12hPF-07817883 600 mg q12hPlacebo
Arm Type Experimental Experimental Experimental Placebo
Arm Description Participants will receive PF-07817883 100 mg q12h for 5d a y s .Participants will receive PF-07817883 300 mg q12h for 5d a y s .Participants will receive PF-07817883 600 mg q12h for 5d a y s .Participants will receive 0 mg q12h for 5 days.
Statistical Methods:
A sufficient number of participants will be screened to achieve a total of approximately 228 
participants, with participants randomly assigned to PF-07817883 100, 300, 600 mg or placebo q12h in approximately a 1:1:2:2 ratio. Assuming 20% of participants will discontinue study drug treatment or have a baseline SARS-CoV-2 RNA level <4 log
10090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 21copi[INVESTIGATOR_014]/mL, approximately 180 participants (60 in each of PF-07817883 600 mg q12h and 
placebo, and 30 in each of PF-07817883 100 and 300 mg q12h) with baseline SARS-CoV-2 
RNA level ≥ 4 log 10copi[INVESTIGATOR_014]/mL are expected to complete Day 5 of the study. Additional
participants may be randomized to ensure 180 participants with baseline SARS-CoV-2 RNA 
level ≥4 log 10copi[INVESTIGATOR_014]/mL who complete study drug treatment.
The sample size is based on the primary efficacy endpoint, change from baseline in SARS-
CoV-[ADDRESS_1163170] SARS-CoV-2 RNA level ≥4l o g
10copi[INVESTIGATOR_014]/mL at baseline. This will exclude data after use of 
prohibited COVID-19 medications and after study treatment discontinuation. The primary analysis will be a Bayesian Emax model applied to the estimates from a mixed model for repeated measures (MMRM) analysis.
A planned formal interim analysis for virological response and safety may be performed to 
assess SARS-CoV-2 RNA level after approximately 50% or more participants, ie, at least 114 participants with baseline SARS-CoV-2 RNA level ≥4 log
10copi[INVESTIGATOR_014]/mL, complete their 
study participation (including viral load assessment) through Day 5. The timing of the interim analysis is contingent on the recruitment rate.
Ethical Considerations:This study is a placebo-controlled trial that will be conducted in participants with 
symptomatic COVID-[ADDRESS_1163171] risk of progressing to severe disease, 
defined as <65 years of age and without underlying medical conditions associated with 
increased risk of developi[INVESTIGATOR_493702]-19 (as outlined in exclusion 
criterion #2). Participants enrolled may benefit from treatment with an antiviral. Although participants may be randomized to placebo, these are participants who are not expected to receive other locally available antiviral therapi[INVESTIGATOR_837512]. For thisstandard risk population currently there is no locally approved standard of care (SoC)treatment available; thus placebo was selected as the appropriate comparator.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )CCI
CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 22The trial-specific risks and burdens for participants includes the requirement to return for 
follow up visits, they may experience discomforts undergoing study assessments (eg, blood samples, ECGs), and they may develop AEs due to study intervention.
1.2. Schema
N = number of completers.
090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 231.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evalua tions or 
assessments required to protect the well-being of the participant.
Table 1. Study Schedule of Assessment
Visit Identifier
Abbreviations used in 
this table may be found 
in Appendix 13Screen Treatment Period F/U ET
(prior 
to Day
33)Notes:
Screening
Day -1Baseline 
Day [1]Day 
[2]Day
[3]Day 
[4]Day
[5]/
EOTDay
[10]Day
[14]Day 
[21]Day 
[33
(28+5)]
/EOS
Visit Window Day -1 to 
Day 10 days NA ±1 
dayNA ±1 day ±1 day ±2 
days±2 days +5 days +3 days Although there is a 3-day window for the Day 5 visit, 
sites should encourage participants to attend on Day 
5 to optimize evaluation of RNA level change at Day 
5.
Study Visit Location S S T S T S S S S S/T S/(T) !Day 33 visit should be conducted in-person at the 
investigational site [S] if NP sample must be 
collected.
!Telehealth visits [T] may be conducted in-person at 
the discretion of the investigator. 
!ET– if visit occurs after Day 21 may be conducted 
by [CONTACT_837539].
ELIGIBILITY
Informed consent X !SeeSection 10.1.3 .
Verify inclusion/ 
exclusion criteriaX !See Section 5.1 andSection 5.2 .
Demographics and 
medical historyX !See Section 8.3.1 .
PHYSICAL EXAMINATION & VITAL SIGNS
Targeted physical examination XX X X X X X X X !SeeSection 8.3.3 .
!Collect at Day 33 visit if participant is symptomatic.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 24Table 1. Study Schedule of Assessment
Visit Identifier
Abbreviations used in 
this table may be found 
in Appendix 13Screen Treatment Period F/U ET
(prior 
to Day
33)Notes:
Screening
Day -1Baseline 
Day [1]Day 
[2]Day
[3]Day 
[4]Day
[5]/
EOTDay
[10]Day
[14]Day 
[21]Day 
[33
(28+5)]
/EOS
Visit Window Day -1 to 
Day 10 days NA ±1 
dayNA ±1 day ±1 day ±2 
days±2 days +5 days +3 days Although there is a 3-day window for the Day 5 visit, 
sites should encourage participants to attend on Day 
5 to optimize evaluation of RNA level change at Day 
5.
Weight, height X !See Section 8.3.2 . Height may be self-reported.
Vital signs X X X X X X X X X !SeeSection 8.3.4 .
!Collect at Day 33 visit if participant is symptomatic.
12-lead ECG X X X X X !Triplicate ECG collected at baseline prior to dosing.
!Day [ADDRESS_1163172]-dose. 
!If ET visit occurs before final ECG assessment on Day 10 visit, ECG should be performed.
!If Day 10 visit is missed, then ECG should be performed at Day 14.
!See Section 8.3.5 for additional information.
LABORATORY ASSESSMENTS
Safety Laboratory Assessments
(Blood) –
Hematology and ChemistryXXX X X !See Section 8.3.6 andAppendix 2 .
!Day [ADDRESS_1163173] dose of study intervention.
!Laboratory assessments not required at screening unless deemed necessary by [CONTACT_837540]. If deemed necessary, laboratory 
assessments at screening will be performed at local laboratory. The medical laboratory test abnormalities 
Safety Laboratory Assessments (Urine)– UrinalysisXXX X X090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 25Table 1. Study Schedule of Assessment
Visit Identifier
Abbreviations used in 
this table may be found 
in Appendix 13Screen Treatment Period F/U ET
(prior 
to Day
33)Notes:
Screening
Day -1Baseline 
Day [1]Day 
[2]Day
[3]Day 
[4]Day
[5]/
EOTDay
[10]Day
[14]Day 
[21]Day 
[33
(28+5)]
/EOS
Visit Window Day -1 to 
Day 10 days NA ±1 
dayNA ±1 day ±1 day ±2 
days±2 days +5 days +3 days Although there is a 3-day window for the Day 5 visit, 
sites should encourage participants to attend on Day 
5 to optimize evaluation of RNA level change at Day 
5.
Other Laboratory 
AssessmentsX X X X* X within [ADDRESS_1163174] be closely 
assessed. If abnormalities cannot be verified, consider conducting local laboratory testing at screening to confirm eligibility for the study. 
!SARS-CoV-2 serology is a part of Other Laboratory Assessment (see Appendix 2 ). Only Day 1 and Day 
10 samples will be assessed for SARS-CoV-2 
serology. 
*Day 10: only SARS-CoV-[ADDRESS_1163175]
(WOCBP only)XX X !Additional Pregnancy tests will be done whenever 1 menstrual cycle is missed or when potential 
pregnancy is otherwise suspected.
!See Section 8.3.7 .
FSH X !When FSH testing is required to confirm 
postmenopausal status, a participant may be screened in the study prior to the test result being 
available as long as the FSH test result confirms 
postmenopausal status prior to dosing.
!SeeSection [IP_ADDRESS] and Appendix 2 .
BIOMARKER ASSESSMENTS
Rapid antigen 
testingX !Confirmed SARS-CoV-[ADDRESS_1163176] kit that is authorized by [CONTACT_454874] a nasal specimen collected within 2 days prior to 
randomization is required.
!SeeSection 8.7.1 .090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 26Table 1. Study Schedule of Assessment
Visit Identifier
Abbreviations used in 
this table may be found 
in Appendix 13Screen Treatment Period F/U ET
(prior 
to Day
33)Notes:
Screening
Day -1Baseline 
Day [1]Day 
[2]Day
[3]Day 
[4]Day
[5]/
EOTDay
[10]Day
[14]Day 
[21]Day 
[33
(28+5)]
/EOS
Visit Window Day -1 to 
Day 10 days NA ±1 
dayNA ±1 day ±1 day ±2 
days±2 days +5 days +3 days Although there is a 3-day window for the Day 5 visit, 
sites should encourage participants to attend on Day 
5 to optimize evaluation of RNA level change at Day 
5.
SARS-CoV-2 RNA 
level assessment(NP)XXX X X X X * X !See Section 8.7.5 .
!Day [ADDRESS_1163177] dose of study intervention.
!If a participant experiences symptom worsening or recurrence after completion of the 5-day treatment with study drug (ie, through Day 33), participants may subsequently attend a site for an unscheduled visit, for NP sample collection to measure SARS-
CoV-2 RNA levels.
*Day 33 NP sample should be collected only if 
participant is symptomatic at Day 21.
Specified protein 
research (plasma biomarkers)XXX X !Day [ADDRESS_1163178] dose of study intervention.
!See Section 8.7.3 .
Retained research 
sample for genetics 
(Prep D1)X !Sample collection is optional.
!Prep D1 Retained Research Samples; if not collected on the designated collection day, collect at the next available time point when biospecimens are being collected in conjunction with a participant visit.
!Refer to Section 8.6.2 .
Retained research samples for 
biomarkers (Prep 
B2.5, Prep R1) XX X X X !Sample collections are optional.
!Day [ADDRESS_1163179] dose of study intervention.
!See Section 8.7.6 .090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 27Table 1. Study Schedule of Assessment
Visit Identifier
Abbreviations used in 
this table may be found 
in Appendix 13Screen Treatment Period F/U ET
(prior 
to Day
33)Notes:
Screening
Day -1Baseline 
Day [1]Day 
[2]Day
[3]Day 
[4]Day
[5]/
EOTDay
[10]Day
[14]Day 
[21]Day 
[33
(28+5)]
/EOS
Visit Window Day -1 to 
Day 10 days NA ±1 
dayNA ±1 day ±1 day ±2 
days±2 days +5 days +3 days Although there is a 3-day window for the Day 5 visit, 
sites should encourage participants to attend on Day 
5 to optimize evaluation of RNA level change at Day 
5.
PK ASSESSMENTS
PK sample (PF-
07817883)XXX X !On Day 1 only, three blood samples for PK will be collected at 30±10, 60±15 and 90±[ADDRESS_1163180]-dose to remain at the site.
!On Day 3, one blood sample for PK will be collected at any time during the study visit.
!On Day 5, one blood sample for PK will be collected. The preferred time of sample collection is predose up to 2 hours before study intervention administration; if a predose sample collection is not possible, collect this sample at any time during the 
visit, even after study intervention has been 
administered.
!Refer to Section 8.5 .
Sample for blood to plasma ratioX !Blood to plasma ratio sample will be collected at60±[ADDRESS_1163181]-dose. Do NOT centrifuge.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 28Table 1. Study Schedule of Assessment
Visit Identifier
Abbreviations used in 
this table may be found 
in Appendix 13Screen Treatment Period F/U ET
(prior 
to Day
33)Notes:
Screening
Day -1Baseline 
Day [1]Day 
[2]Day
[3]Day 
[4]Day
[5]/
EOTDay
[10]Day
[14]Day 
[21]Day 
[33
(28+5)]
/EOS
Visit Window Day -1 to 
Day 10 days NA ±1 
dayNA ±1 day ±1 day ±2 
days±2 days +5 days +3 days Although there is a 3-day window for the Day 5 visit, 
sites should encourage participants to attend on Day 
5 to optimize evaluation of RNA level change at Day 
5.
PK micro-sampling 
(PF-07817883)XX X !PK micro-sample(s) will be collected by [CONTACT_837541]-sampling device on Day 1, 60±[ADDRESS_1163182]-dose simultaneously with the PK sample draw.
!A Tasso micro-sample will be self-collected at homebefore administration of the second dose. This can 
occur on Day [ADDRESS_1163183] dose is taken in the evening on Day 1.
!Self-collected at home by [CONTACT_837541]-sampling device at the following timepoints:
!Day 2 before the evening dose, 
!Day 4 after the morning dose at the following times: 1 sample between 30 to 90 minutes, 1 
sample between 2 to 6 hours, and 1 sample 8 to 
12 hours after the dose (the last sample should be collected before the evening dose).
!Tasso micro-sampling can occur regardless of whether this coincides with a site visit.
!Refer to Section 8.5 .
RANDOMIZATION
Randomization X !At randomization, the participant enrollment number 
and dose level allocation are assigned.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 29Table 1. Study Schedule of Assessment
Visit Identifier
Abbreviations used in 
this table may be found 
in Appendix 13Screen Treatment Period F/U ET
(prior 
to Day
33)Notes:
Screening
Day -1Baseline 
Day [1]Day 
[2]Day
[3]Day 
[4]Day
[5]/
EOTDay
[10]Day
[14]Day 
[21]Day 
[33
(28+5)]
/EOS
Visit Window Day -1 to 
Day 10 days NA ±1 
dayNA ±1 day ±1 day ±2 
days±2 days +5 days +3 days Although there is a 3-day window for the Day 5 visit, 
sites should encourage participants to attend on Day 
5 to optimize evaluation of RNA level change at Day 
5.
STUDY INTERVENTION
Study intervention 
administration Day 1 through Day 5
(10 doses total)!If 1 dose was administered on Day 1, study intervention administration should end on Day 6(total 10 doses).
!All subsequent doses may be self-administered outside the study clinic (eg, at home).
!See Section 6.1 for additional information.
CONCOMITANT TREATMENT(S)
Prior/concomitant medication(s)XX X X X X X X X !See Section 6.9 .
Adjunctivetherapeutic 
proceduresXX X X X X X X X !Will be collected through the Day 33 visit.
!Please see Section 8.3.8 .
STUDY PROCEDURES& ASSESSMENTS
Collect/update secondary contact[CONTACT_837542] X !S
eeSection 8.1.[ADDRESS_1163184] 
supplemental 
oxygen requirementsXX X X X X X X X !SeeSection 8.2.4 .090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 30Table 1. Study Schedule of Assessment
Visit Identifier
Abbreviations used in 
this table may be found 
in Appendix 13Screen Treatment Period F/U ET
(prior 
to Day
33)Notes:
Screening
Day -1Baseline 
Day [1]Day 
[2]Day
[3]Day 
[4]Day
[5]/
EOTDay
[10]Day
[14]Day 
[21]Day 
[33
(28+5)]
/EOS
Visit Window Day -1 to 
Day 10 days NA ±1 
dayNA ±1 day ±1 day ±2 
days±2 days +5 days +3 days Although there is a 3-day window for the Day 5 visit, 
sites should encourage participants to attend on Day 
5 to optimize evaluation of RNA level change at Day 
5.
Participant-
completed study diary (revised COVID-19 signs 
and symptoms, and 
global impression questions)Every day from Day 1 through Day 29 !Revised COVID-19 signs and symptom eDiary assessments should be completed pre-dose, prior to other study procedures such as ECG recordings and 
laboratory assessments.
!SeeSection 8.2.1 andSection 8.2.5 .
Staff review of study diaryXX XXXX !See Section 8.2.1 .
Participant-
completed study 
intervention logDay 1 through Day 5 !Study intervention log should be completed daily on 
Day 1 through Day 6 if only 1 dose was administered on Day 1.
!See Section 6.[ADDRESS_1163185] COVID-19-related medical visitsXX X X X X X !COVID-19-related medical visits a participant has attended since the last assessment will be collected.
!See Section 8.2.2 .
Retrieval of unused study intervention and empty study intervention 
containersXX X X !If the Day [ADDRESS_1163186] dose of 
study intervention, the study intervention log, empty 
study intervention containers, and unused study 
intervention should be returned at the next in-person visit.
!See Section 6.5 .090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 31Table 1. Study Schedule of Assessment
Visit Identifier
Abbreviations used in 
this table may be found 
in Appendix 13Screen Treatment Period F/U ET
(prior 
to Day
33)Notes:
Screening
Day -1Baseline 
Day [1]Day 
[2]Day
[3]Day 
[4]Day
[5]/
EOTDay
[10]Day
[14]Day 
[21]Day 
[33
(28+5)]
/EOS
Visit Window Day -1 to 
Day 10 days NA ±1 
dayNA ±1 day ±1 day ±2 
days±2 days +5 days +3 days Although there is a 3-day window for the Day 5 visit, 
sites should encourage participants to attend on Day 
5 to optimize evaluation of RNA level change at Day 
5.
Study intervention 
accountabilityX X X X X X [if 
needed]!Study intervention accountability is also performed at the Day 10 visit if the participant administered treatment after the Day 5 visit was conducted.
!Study intervention accountability check at Day 2 and Day 4 will be an optional phone call.
!See Section 6.5 .
Contraception 
check XX X X X X X X X !See Section 5.3.1 .
Vital status check XX !Verify mortality status of participants, if needed.
!See Section 8.1.1 .
Serious and nonserious AE 
monitoringXX X X X X X X X X X !AEs should be assessed by [CONTACT_3553] a telehealthvisit if not possible via an in-person visit.
!See Section 8.4 for additional information.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163187] pharmacological and safety information to inform dose selection of PF-07817883 in later stage Phase 2/3 studies.
2.2. Background
In December 2019, COVID-19 was identified as a new, potentially fatal, respi[INVESTIGATOR_705076], SARS-CoV-2. The WHO declared COVID-19 a Public Health Emergency of International Concern on 20 January 2020 and further characterized the disease outbreak as a pandemic on 11 March 2020.
1
COVID-19 manifests as a wide range of illnesses, from asymptomatic infection to severe pneumonia, ARDS, and death. While the majority of cases (approximately 80%) are asymptomatic or mild,
2patients who are hospi[INVESTIGATOR_21391]-[ADDRESS_1163188] significant 
morbidity and mortality,3,4and are at increased risk of developi[INVESTIGATOR_705077], acute cardiac injury, thromboembolic events and/or kidney injury.5-7Moreover, other 
comorbidities, such as hypertension, obesity, and diabetes, as well as older age and male sex increase the risk for worse outcomes.
8,9
The coronavirus Mprois a virally encoded enzyme that is critical to the SARS-CoV-2
replication cycle, analogous to other obligatory virally encoded proteases (eg, HIV protease, HCV protease). Mutagenesis experiments with other coronaviruses and pi[INVESTIGATOR_295346]-CoV-2 (pi[INVESTIGATOR_295347]-like supercluster) have demonstrated that the activity of the M
prois essential for viral replication. No close human analogs of coronavirus 
Mproenzymes are known, suggesting that appropriate Mproinhibitors may function as 
selective inhibitors of SARS-CoV-2 and other coronaviruses as therapeutic agents.
Inhibition of the SARS-CoV-2 Mproby [CONTACT_837543][INVESTIGATOR_837513]-to-moderate COVID-19 
patients with high risk of progression to severe disease. But some high-risk patients may be 
ineligible for PAXLOVID due to DDIs. Hence, there remains an important need for additional safe and more effective therapeutic interventions.
2.2.1. Nonclinical Studies of PF-07817883
Data from nonclinical studies support the planned clinical trials with PF-07817883; these 
studies are described in the IB.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163189] clinical study using PF-07817883. It is a six-part study. PART-1 is a 
SAD study, PART-2 is a MAD study, PART-3 is a rBA/FE study, PART 4 is a ME study, PART-5 is a DDI study and PART-6 is a SE study.
PART-1 included 2 interleaving cohorts with a total of 16 participants with 3-period cross-
over in each cohort. For each period, up to 6 participants received a single oral dose of PF-07817883 and up to 2 participants received placebo. Single doses of PF-07817883 ranged from 150 mg to 4000 mg.  in Cohort 1 were  
 and Other  090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )CCI CCI
CCI
CCI
CCI
CCICCI
CCI
CCI CCI
CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 34 
PART-2 included 3 cohorts evaluating safety, tolerability, and PK data at 200 mg, 600 mg, 
and 1500 mg doses of PF-07817883 or placebo administered BID for up to 10 days. As of 18 
January 2023, 18 participants were randomized in 3 cohorts in PART-2.  
 in Cohort 4 (PF-07817883 600 mg BID or placebo) of PART-2 due to Other 
() .
PART-[ADDRESS_1163190] of steady state PF-07817883 600 mg on PK of midazolam in healthy participants.
[IP_ADDRESS]. Safety Overview
The preliminary data collected (data snapshot 18 January 2023) in PART-1, PART-2, and 
(data snapshot 06 February 2023) in PART-4 and PART-5 (Cohort 11) of the Phase 1 study 
(C5091001) demonstrated an acceptable safety profile at single doses of PF-[ADDRESS_1163191] been no deaths, SAEs or S[LOCATION_003]Rs reported.  
 
 
 
 
There were no obvious trends in, or 
association of, TEAEs with dose level of PF-07817883 in PART-1, PART-2, PART-4, or 
PART-5 (Cohort 11); however, the small numbers of participants studied at each dose level do not permit any definitive conclusions about the relationship between dose and tolerability.
Further details on the clinical safety of PF-07817883 are provided in the current IB.
[IP_ADDRESS]. Summary of PF-07817883 Pharmacokinetics in Humans
 
 
 
 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
CCICCICCI
CCI
CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 35090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 36Further details on the clinical PK of PF-07817883 are provided in the current IB.
2.3. Benefit/Risk Assessment
The purpose of the study is to generate safety, tolerability and PK data for further clinical
development of PF-07817883 as a potential new, pharmacological agent for the treatment of COVID-19. PF-07817883 has been evaluated in non-clinical studies and in an ongoing study (C5091001) in healthy adult participants.
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of PF-07817883 may be found in the Investigator’s Brochure, which is the SRSD for this study.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 372.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) PF-07817883090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163192] risk for progression to severe disease and hospi[INVESTIGATOR_059]. In the context of the global pandemic public health emergency, this treatment could play an important role in alleviating current pressures on health care systems globally.
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the ongoing COVID-[ADDRESS_1163193] dose to use in high-risk populations. An independent IRC will be responsible for monitoring the safety of participants at regularly scheduled intervals throughout the duration of the study and for assessing efficacy and futility at the time of the planned interim analysis according to the IRC Charter.
3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS
Objectives Endpoints Estimands
Primary: Primary: Primary: 
!To describe the effect of 
PF-07817883 treatment versus placebo on SARS-CoV-2 RNA 
levels in NP samples in non-
hospi[INVESTIGATOR_837508]-19.!Change from baseline in SARS-CoV-2 RNA level on Day 5.!E1: The estimand is the difference between the PF-[ADDRESS_1163194] 
SARS-CoV-2 RNA level 
≥4l o g
10copi[INVESTIGATOR_014]/mL at baseline. This 
analysis will exclude data after use of 
prohibited COVID-19 medications and after study treatment discontinuation.
Secondary: Secondary: Secondary: 
!To describe the effect of PF-07817883 treatment versus placebo on SARS-CoV-2 RNAlevels in NP samples in non-!Change from baseline in SARS-CoV-2 RNA level on Days 3, 10, and 14.!E1: The estimand is the difference between the PF-07817883 dose groups and placebo in mean change from baseline in SARS-CoV-2 RNA level in NP samples in the population of non-090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163195] 
SARS-CoV-2 RNA level 
≥4l o g
10copi[INVESTIGATOR_014]/mL at baseline. This 
analysis will exclude data after use of 
prohibited COVID-19 medications and after study treatment discontinuation.
!To describe the safety and tolerability of PF-07817883relative to placebo in the treatment of non-hospi[INVESTIGATOR_057], symptomatic, adult participants 
with COVID-19.!Incidence of TEAEs.
!Incidence of SAEs and AEs 
leading to discontinuations.
!Incidence of clinically significant 
abnormal laboratory values, vital 
signs, and ECGs.!NA
Tertiary/Exploratory: Tertiary/Exploratory: Tertiary/Exploratory:
!To assess the effect of 
PF-07817883 treatment on the duration and severity of signs and symptoms in non-
hospi[INVESTIGATOR_057], s
ymptomatic, 
adult participants with 
COVID-19.!Proportion of participants with any 
targeted signs and symptoms attributed to COVID-19 over time .
!Proportion of participants with anytargeted severe sign or symptom attributed to COVID-19 over time.
!Number of participants with sustained alleviation of all targeted signs/symptoms over time.
!Number of participants with sustained resolution of all targeted 
signs and symptoms over time.
!Duration of targeted COVID-19 
sign or symptom.
!Progression to a worsening status in 1 or more self-reported COVID-19-associated symptoms over time.
!Proportion of participants with symptom rebound at Day 10, 14, 
and 21.!NA
!To assess the effect of
PF-07817883 treatment onCOVID-19-related medical visits, hospi[INVESTIGATOR_837514]-cause mortality in non-
hospi[INVESTIGATOR_057], symptomatic, adult participants with COVID-19.!Proportion of participants with COVID-19 related medical visitsor hospi[INVESTIGATOR_059], over time. 
!Proportion of participants with death (all cause) over time. 
!Number of days in hospi[INVESTIGATOR_837515]-19 related hospi[INVESTIGATOR_837516].!NA
!To determine the PK of PF-07817883 in non-hospi[INVESTIGATOR_057], symptomatic, 
adult participants with COVID-
19.!PF-07817883 PK in plasma and whole blood (if feasible).!NA
!To describe the effect of PF-07817883 treatment versus placebo on SARS-CoV-2 RNAlevels in NP samples in non-!Change from Day 5 in SARS-CoV-2 RNA level at Days 10, 14 and 21.
!Change from baseline in SARS-CoV-2 RNA levels at Days 21 and 33.!NA090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 40Objectives Endpoints Estimands
hospi[INVESTIGATOR_837517]-19.!Proportion of participants with 
SARS-CoV-2 RNA level <LLOQ in NP samples over time.
!Proportion of participants with viral rebound at Day 10, Day 14, or Day 21.
!To describe the effect of PF-07817883 treatment on 
infectivity of SARS-CoV-2 
collected from NP samples.!Change from baseline in SARS-CoV-2 infectious titer on Days 3, 5, 
10 and 14, and Days 21 and 33 (if 
data permit).!NA
4. STUDY DESIGN
4.1. Overall DesignThis is a Phase 2B, double-blind, randomized, placebo-controlled, parallel group, dose 
ranging study to assess the effect of PF-07817883 treatment on SARS-CoV-2 RNA levelreduction in NP samples in non-hospi[INVESTIGATOR_057], symptomatic, adult participants with COVID-19. Approximately 228 eligible participants with a confirmed diagnosis of SARS-CoV-2 infection are planned to be randomized into the study to ensure approximately 180participants with baseline SARS-CoV-2 RNA level ≥4 log
10copi[INVESTIGATOR_014]/mL complete the study
drug treatment. Participants will be randomized in a 1:1:2:2 ratio to receive PF-07817883100, 300, or 600 mg, or placebo orally q12h for 5 days (10 doses total). Study visits should take place at the investigational site.
The total study duration is up to [ADDRESS_1163196] administration of the study intervention.
An independent IRC will review unblinded data to ensure the safety of participants 
throughout the duration of the study, as specified in the IRC Charter. In addition to safetyreviews, the IRC will review the following:
!A planned formal interim analysis for virological response and safety may be performed to assess SARS-CoV-2 RNA level after approximately 50% or more participants, ie, at least 114 participants with baseline SARS-CoV-2 RNA level ≥4 
log
10copi[INVESTIGATOR_014]/mL, complete their study participation (including viral load assessment) 
through Day 5. The timing of the interim analysis will be contingent on the recruitment rate.
Subsequent to the planned interim analysis, there will be [ADDRESS_1163197] of an investigational agent on 
reducing SARS-CoV-2 viral RNA level. The study is designed as a dose-ranging study to 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163198] since been removed as treatment options due to diminished efficacy with the emergence of SARS-CoV-2 variants.
10,11Antivirals such as PAXLOVID
and remdesivir IV are available and considered preferred therapy for non-hospi[INVESTIGATOR_119800], while molnupi[INVESTIGATOR_837518]-19 Treatment Guidelines Panel.
11However, these therapeutics are limited to outpatient populations with 
mild-to-moderate COVID-19 infection at risk for progressing to severe disease. Furthermore, some high-risk patients may be ineligible for PAXLOVID due to DDIs, and remdesivir may be inaccessible for some patients as it requires administration in a health care setting and returning for 3 subsequent days for daily IV dosing.
Despi[INVESTIGATOR_95053], there remains an important need for additional safe and more 
effective therapeutic interventions that do not require administration in a healthcare setting, are not limited by [CONTACT_705109], and with a risk/benefit profile supportive of administration to a broader patient population. The direct reduction of viral replication, through inhibition of other critical viral enzymes, offers an important mechanism as monotherapy or in combination, to achieve greater patient benefit.
Efficacy assessments (including participant reported COVID-19-related symptoms and 
severity, and COVID-19-related medical visits) will be collected through Day 33. The symptom endpoint includes those recommended by [CONTACT_837544]-19, and which are expected to be dynamic and improve with effective anti-SARS-CoV-2 therapy. NP samples will be collected at specified timepoints to assess SARS-CoV-2 RNA level over time.
This study uses a randomized, double-blind, placebo-controlled design, which is a well-
accepted approach for evaluating efficacy in a clinical research setting. Placebo was selected as the comparator since as of this date there is no globally approved SoC treatment for this 
patient population. Participants in either treatment group may receive SoC therapy so long as 
it is not prohibited under Section 5.1 or Appendix 9.
4.2.1. Diversity of Study Population
Diversity of study population in this protocol applies to sites in the US only. The diversity 
strategy will include sites with the potential to support the recruitment of diverse populations. Reasonable attempts will be made to enroll participants to ensure the study population is representative of the patient population that will be treated with PF-07817883 in clinical practice. The following strategies may be explored in support of diverse recruitment efforts:
!Selecting sites that have access to diverse participants within their locale.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 42!Creating and completing individual site recruitment plans in collaboration with sites.
!Have proactive discussions with investigator sites throughout the enrollment period to 
assess and reevaluate site specific strategies as needed to best position each site for the most diverse representation enrollment outcomes.
!Developi[INVESTIGATOR_837519].
!Translating all patient-facing materials into US Spanish.
!Providing investigators with recruitment materials for both potential participants and other HCPs.
!Educating site staff on the importance of including diverse participants.
!Monitor diverse enrollment to identify potential opportunities to include diverse populations.
4.2.2. Choice of Contraception/Barrier Requirements 
Studies to evaluate the developmental toxicity of PF-[ADDRESS_1163199] not been 
conducted. Therefore, the use of a highly effective method of contraception is required (see Appendix 4 ).
4.2.3. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further analyses which may, for 
example, provide greater understanding of the study intervention.
4.3. Justification for Dose
The dosing regimens to be evaluated in this study are placebo, 100, 300 and 600 mg 
PF-07817883 q12h administered orally for 5 days. Dose selection for this study included consideration of all relevant available preclinical and clinical data, including repeat-dose toxicology studies, clinical safety, and PK  data from the ongoing Phase 1 study (C5091001), 
and in vitro pharmacology studies with PF-07817883.
A preliminary population PK model was developed using PK data (unaudited) from the 
single ascending dose and multiple ascending dose parts of the Phase 1 study (C5091001). Following the first dose of 100, 300 and 600 mg of PF-07817883 q12h, median unbound (total) C
trough of PF-07817883 are predicted to be approximately 43 (92), 119 (253) and 226 
(482) ng/mL, ie, approximately 1.3, 3.5 and 6.6-fold higher than the in vitro EC 90(total) of 
ng/mL determined in dNHBE cells (equivalent to free in vitro EC 90of 70 nM, fu, 
human= ), respectively. As the majority of antivirals are administered to maintain concentrations either at or above the EC
90, lower doses below 100 mg are not planned for this 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
CCI
CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163200] variability of 60%, more than 63, 96 and 99% of the participants, respectively, are predicted to maintain free PF-[ADDRESS_1163201] participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
1. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.
2. Participants ≥18 to <65 years of age at the time of the Screening Visit.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 44!WOCBP may be enrolled.
!All fertile participants must agree to use a highly effective method of 
contraception. Refer to Appendix 4 for reproductive criteria for male ( Section 
10.4.1) and female ( Section 10.4.2 ) participants.
Disease Characteristics:
3. Confirmed SARS-CoV-[ADDRESS_1163202] be available to confirm eligibility.
4. Initial onset of signs/symptoms attributable to COVID-[ADDRESS_1163203] 1 of the specified signs/symptoms attributable to COVID-19 present on the day of randomization (see Appendix 10 for criteria).
5.2. Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
1. Current need for hospi[INVESTIGATOR_295361] 24h 
after randomization in the clinical opi[INVESTIGATOR_91382].
Medical conditions:
2. Has at least 1 characteristic or underlying medical condition (self-report is 
acceptable) associated with an increased risk of developi[INVESTIGATOR_837509]-19. The list of the characteristics or conditions includes:
!BMI≥30 kg/m
2;
!Current smoker (cigarette smoking within the past 30 days) and history of at least 
100 lifetime cigarettes;
!Chronic lung disease (ie, bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, pulmonary hypertension);
!Asthma, requiring daily prescribed therapy;
!Cardiac vascular disease, defined as history of any of the following: myocardial infarction, stroke, transient ischemic attack, heart failure, angina with prescribed nitroglycerin, coronary artery by[CONTACT_9292], percutaneous coronary intervention, carotid endarterectomy, and aortic by[CONTACT_6476];
!Type 1 or Type 2 diabetes mellitus;090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 45!Chronic Kidney Disease requiring dialysis;
!Neurodevelopmental disorders (eg, cerebral palsy, Down’s syndrome) or other 
conditions that confer medical complexity (eg, genetic or metabolic syndromes and severe congenital anomalies);
!Active cancer other than localized skin cancer, including those requiring treatment (including palliative treatment), as long as the treatment is not among the prohibited medications that must be administered/continued during the trial period;
!Medical-related technological dependence (eg, CPAP [not related to COVID-19]).
3. Known medical history of active liver disease, including chronic or active hepatitis B 
or C infection, primary biliary cirrhosis, Child-Pugh Class B or Class C, or acute liver failure.
4. History of hypersensitivity or other contraindication to any of the components of the 
study interventions, as determined by [CONTACT_093].
5. Suspected or confirmed concurrent active systemic infection other than COVID-19 
that may interfere with the evaluation of response to the study intervention.
6. Immunocompromised with ≥1 of the following:
a. Solid organ (eg, liver, heart, lung or kidney) transplant recipi[INVESTIGATOR_837510].
b. Receipt of CAR-T-cell therapy or HCT either within 2 years of transplantation 
or receiving immunosuppressive therapy.
c. Moderate or severe primary immunodeficiency (eg, DiGeorge syndrome, 
Wiskott-Aldrich syndrome).
d. Use of at least 1 of the following immune-weakening medications:
i. Has received corticosteroids equivalent to prednisone ≥[ADDRESS_1163204] 14 consecutive days within 30 days prior to study entry.
ii. Active treatment causing significant immunosuppression, including 
alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents, TNF blockers, or other highly immunosuppressive drugs such as biologics.
e. Hematological malignancy (including leukemia, lymphoma and myeloma) or 
active immunosuppressive treatment for solid tumor.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 46f. HIV infection with CD4 cell count <[ADDRESS_1163205] 6 months of screening.
7. Known severe renal impairment (eGFR of <30 mL/min/1.73 m2within 6 months of
the screening visit, using the serum creatinine-based CKD-EPI [INVESTIGATOR_14420]12).
8. Oxygen saturation of <92% on room air obtained at rest within 24h prior to 
randomization.
a. NOTE: For a potential participant who regularly receives chronic 
supplementary oxygen for an underlying lung condition, oxygen saturation 
should be measured while on their standard home oxygen supplementation.
9. Any comorbidity requiring hospi[INVESTIGATOR_5478]/or surgery within 7 days prior to study 
entry, or that is considered life threatening within 30 days prior to study entry, as determined by [CONTACT_093].
10. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.
Prior/Concomitant Therapy:
11. Current use of any prohibited concomitant medication(s). Refer to Section 6.9 Prior 
and Concomitant Therapy.
12. Use of any locally available oral or injectable antiviral medication intended to treat 
symptomatic SARS-CoV-2 infection before and at enrollment are excluded. After enrollment, locally available SARS-CoV-2 treatment (including but not limited to molnupi[INVESTIGATOR_42654], mAbs, outpatient IV remdesivir, convalescent plasma) will be permitted per investigator judgement. Note: PAXLOVID is contraindicated to be administered concurrently with the study intervention due to DDI risk (refer to Section 6.9 ).
13. Expected to receive any dose of a SARS-CoV-2 vaccine within 14 days of 
randomization or during the study.
Prior/Concurrent Clinical Study Experience:
14. Current or previous administration with an investigational product (drug or vaccine) 
within 30 days (or as determined by [CONTACT_19970]) or [ADDRESS_1163206] dose of study intervention used in this study (whichever is longer). Authorized or products with conditional approval are not considered investigational.
15. Known prior participation in this trial.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 47Diagnostic Assessments:
16. Laboratory assessments not required at screening unless deemed necessary by [CONTACT_837538]. If deemed necessary, laboratory assessments at 
screening will be performed at local laboratory. The medical laboratory test abnormalities within [ADDRESS_1163207] be closely assessed. If abnormalities cannot be verified, consider conducting local laboratory testing at screening to confirm eligibility for the study .
17. Known history of any of the following abnormalities in clinical laboratory tests 
(within past 6 months of the screening visit):
!T bili ≥2 × ULN (except for Gilbert’s syndrome)
!AST or ALT ≥ 2.5 × ULN
!Abs neutrophil count <1000/mm
3.
18. Baseline standard 12-lead ECG that demonstrates clinically relevant abnormalities 
that may affect participant safety or interpretation of study results (eg, QTcF >[ADDRESS_1163208]-degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 ms, this interval should be rate corrected using the Fridericia method only and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 ms, or QRS exceeds 120 ms, the ECG should be repeated twiceand the average of the 3 QTcF or QRS values used to determine the participant’s eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
Other Exclusion Criteria:
19. Females who are pregnant or breastfeeding.
20. Investigator site staff directly involved in the conduct of the study and their family 
members, site staff otherwise supervised by [CONTACT_093], and sponsor and sponsor 
delegate employees directly involved in the conduct of the study and their family members.
5.3. Lifestyle Considerations
5.3.1. Contraception The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant and his or her partner(s) from the permitted list of contraception methods (see Appendix 4 ,
Section 10.4.4) and will confirm that the participant has been instructed in its consistent and 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163209] use. At time points indicated in the SoA, the investigator or designee will inform the 
participant of the need to use highly effective contraception consistently and correctly and 
document the conversation and the participant’s affirmation in the participant’s chart.Participants need to affirm their consistent and correct use of at least [ADDRESS_1163210] the participant to call immediately if the 
selected contraception method is discontinued and document the requirement to use an alternate protocol-specified method, including if the participant will no longer use abstinence as the selected contraception method, or if pregnancy is known or suspected in the participant or partner.
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently enrolled in the study. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the CONSORT publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAE.
Individuals who do not meet the criteria for participation in this study (screen failure) may 
not be rescreened.
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study interventions are all prespecified investigational and medicinal products, medical 
devices, and other interventions (eg, surgical and behavioral) intended to be administered to the study participants during the study conduct.
For the purposes of this protocol, study intervention refers to PF-07817883 100 mg, 300 mg 
and 600 mg (2 x 300 mg) or matching placebo tablets.
6.1. Study Intervention(s) Administered
Study Intervention(s)
Intervention 
NamePF-07817883 PF-07817883 PF-07817883 Placebo for 
PF-07817883
Arm Name
(group of 
participantsreceiving a specific treatment or no treatment)PF-07817883100 mg q12hPF-07817883300 mg q12hPF-07817883600 mg q12hPlacebo
Type Drug Drug Drug Placebo090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 49Study Intervention(s)
Dose FormulationTablet Tablet Tablet Tablet*
Unit Dose Strength(s)100 mg 300 mg 300 mg 0 mg
Dosage Level(s) 100 mg q12h for 5d a y s300 mg q12h for 5d a y s600 mg q12h for 5d a y s0 mg q12h for 5d a y s
Route of AdministrationOral Oral Oral Oral
Use Experimental Experimental Experimental Placebo
IMP or NIMP/AxMPI[INVESTIGATOR_837520].
Refer to the IPM.Provided centrally 
by [CONTACT_456].
Refer to the IPM.Provided centrally 
by [CONTACT_456].
Refer to the IPM.Provided centrally 
by [CONTACT_456].
Refer to the IPM.
Packaging and 
LabelingStudy intervention 
will be provided in 
bottles. Each bottlewill be labeled as required per country requirement.Products will be 
provided with 
blinded labels.Study intervention 
will be provided in
bottles. Each bottle will be labeled as required per country requirement. Products will be 
provided with 
blinded labels.Study intervention 
will be provided in 
bottles. Each bottle will be labeled as required per country requirement. Products will be 
provided with 
blinded labels.Study intervention 
will be provided in 
bottles. Each bottle will be labeled as required per country requirement. Products will be 
provided with 
blinded labels.
Current/Former Name(s) or Alias(es)PF-07817883 PF-07817883 PF-07817883 NA
* 2 tablet types for placebo to match with  PF-07817883 100 mg and 300 mg, respectively.
Study Arm(s)
Arm Title PF-07817883 100 mgPF-07817883 300 mgPF-07817883 600 mgPlacebo
Arm Type Experimental Experimental Experimental Placebo
ArmDescriptionParticipants will receive PF-07817883 
100 mg q12h from 
Day 1 through Day 5.Participants will receive PF-07817883 
300 mg q12h from 
Day 1 through Day 5.Participants will receive PF-07817883 
600 mg q12h from 
Day 1 through Day 5.Participants will receive placebo 0 mg 
q12h from Day 1 
through Day 5.
Associated Intervention LabelsPF-07817883 (100 mg q12h)PF-07817883 (300 mg q12h)PF-07817883 (600 mg q12h)Placebo q12h090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163211] dose of study intervention on Day 1, during the in-
person visit. All subsequent doses may be self-administered outside the study clinic (eg, at home). The study intervention should be taken every 12 hours (±4 hours), and not more than twice in a calendar day. Depending on the time of first dose, the timing of the second dose may be adjusted slightly to allow the participant/caregiver to select a convenient [ADDRESS_1163212] dose. Once the dosing schedule is adjusted, all subsequent doses should be taken every 12 hours (±4 hours).
Participants may take the study intervention with or without food. Refer to the IPM for 
additional dosing and administration instructions.
If a dose is delayed, it should be taken as soon as possible, but no later than 4 hours before 
the next scheduled dose. Participants should not double up the next dose of study drug in order to “make up” what had been missed. Dosing should be stopped at the end of the treatment period (10 doses total). Any remaining tablets and/or capsules at the end of 5 days (or 6 days if only one dose was administered on Day 1) should be returned.
6.2. Preparation, Handling, Storage, and Accountability
1. The investigator or designee must confirm that appropriate conditions (eg, 
temperature) have been maintained during transit for all study interventions received 
and any discrepancies are reported and resolved before use of the study intervention. 
2. Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply, prepare, and/or administer study intervention. 
3. All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff. At 
a minimum, daily minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking days must indicate the minimum and maximum temperatures since previously documented upon return to business.
4. Any excursions from the study intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery along with actions taken. The site should actively pursue options for returning the study intervention to labeled storage conditions, as soon as possible. Once an excursion is identified, the study intervention must be 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163213] participants on the proper storage requirements for take -home study intervention.
6. Study interventions should be stored in their original containers.
7. The investigator, institution, head of the medical institution (where applicable), or 
authorized site staff is responsible for study intervention accountability, 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records), such as the IPAL or sponsor-approved equivalent. All study interventions will be accounted for using a study intervention accountability form/record. All study intervention that is taken home by [CONTACT_2299], both used and unused, must be returned to the investigator by [CONTACT_2299]. Returned study 
intervention must not be redispensed to the participants.
8. Further guidance and information for the final disposition of unused study 
interventions are provided in the IPM. All destruction must be adequately documented. If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by [CONTACT_4618].
Upon identification of a product complaint, notify the sponsor within [ADDRESS_1163214] in the bottles provided throughout the course of dosing.
Study intervention and placebo will be dispensed by [CONTACT_837545]. The study intervention will be administered in a blinded fashionto the participants.
6.3. Assignment to Study Intervention
Allocation of participants to treatment groups will proceed through the use of an IRT system. 
The site personnel (study coordinator or specified designee) will be required to enter or select information including but not limited to the user’s ID and password, the protocol number, and the participant number. The site personnel will then be provided with a randomization number corresponding to the assigned treatment group, and DU or container number(s) when 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163215] be stored in the site’s files.
Study intervention will be dispensed at the study visits summarized in the SoA.
The study -specific IRT reference manual and IPM will provide the contact [CONTACT_446973].
Returned study intervention must not be redispensed to the study participants.6.4. Blinding
This is a double-blind study.6.4.1. Blinding of ParticipantsParticipants and their caregivers will be blinded to their assigned study intervention.6.4.2. Blinding of Site PersonnelInvestigators and other site staff will be blinded to participants’ assigned study intervention. 
Participants will be assigned to receive study intervention according to the assigned treatment 
group from the randomization scheme. Investigators will remain blinded to each participant’s assigned study intervention throughout the course of the study.
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study intervention records at the site(s) to verify that randomization/dispensing has been done accurately.
6.4.3. Blinding of the Sponsor
Sponsor staff will be blinded to participants’ assigned study intervention, except for sponsor 
staff involved in the assignment or distribution of study intervention. Sponsor staff who are not directly involved with the conduct of this study will prepare analyses and documentation containing unblinded data while the study is ongoing to support interactions with the IRC. The study will be unblinded after all participants complete the Day 33 visit (or ET prior to Day 33 visit) and analyses through Day 33, including the primary efficacy endpoint analyses, will be conducted. Details of the timing of unblinding will be outlined in the Unblinding Plan.
6.4.4. Breaking the BlindThe IRT will be programmed with blind-breaking instructions. In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety must always be the first consideration in making such a determination. If the investigator decides that unblinding is warranted, the investigator should make every effort to contact [CONTACT_705126] a participant’s treatment assignment unless this could delay further management 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 53of the participant. If a participant’s treatment assignment is unblinded, the sponsor must be 
notified within [ADDRESS_1163216] dose.
Site personnel will review the participant-completed dosing diary at in person visits (Day 3 
and Day 5) and during an (optional) phone call on Day 2 and Day 4, during the study intervention period, preferably after the participant has self-administered the morning dose of the study intervention. If any noncompliance with dosing is suspected, site personnel will remind the participant of the relevant study procedures and/or entering the information in the diary as applicable.
When participants are dosed at the site, they will receive study intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose administered in the clinic will be recorded by [CONTACT_837546]. The dose of study intervention and study participant identification will be confirmed at the time of dosing by a member of the study site staff other than the person administering the study intervention.
When participants self-administer study intervention(s) at home, compliance with study 
intervention will be assessed at each visit. Compliance will be assessed by [CONTACT_522867]/capsules during the site visits and documented in the source documents and CRF. Deviation(s) from the prescribed dosage regimen should be recorded.
A record of the number of PF-[ADDRESS_1163217] be maintained and reconciled with study intervention and compliance records.
The following noncompliance cases will be considered medication errors (see Section 
8.4.10).
!Participants interrupting study intervention for 2 consecutive doses;
!Participants who have an overall study intervention compliance <80% or >115%.
In addition to the above listed-medication errors, any deviation from protocol-specified
dosing (eg, missed single dose or partial dose) should be recorded as a protocol deviation andthe investigator or designee is to counsel the participant/guardian and ensure steps are takento improve compliance.
6.6. Dose Modification
Dose modification for PF-07817883 is not allowed.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163218]-of-care treatments, as advised by [CONTACT_219875].
6.8. Treatment of Overdose
For this study, a dose of >12 tablets of “PF-07817883 300 mg or placebo” or >36 tablets of 
“PF-07817883 100 mg or placebo”, or any combination of these tablets achieving maximum nominal dose of  mg within a 24-hour time period, will be considered an overdose.
There is no specific treatment for an overdose.In the event of an overdose, the investigator should:
1. Contact [CONTACT_185605] 24 hours.2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities as 
medically appropriate and at least until the next scheduled follow-up.
3. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
4. Overdose is reportable to [COMPANY_007] Safety only when associated with an SAE.
5. Obtain a blood sample for PK analysis within [ADDRESS_1163219] dose of 
study intervention if requested by [CONTACT_138830] (determined on a case by
[CONTACT_413]).
Decisions regarding dose interruptions or modifications will be made by [CONTACT_705127].
6.9. Prior and Concomitant Therapy
Prior Therapy
Use of an antiviral or mAb therapy for the treatment of COVID-19 within 30 days or 5 half-
lives (whichever is longer) prior to screening is prohibited.
Current or previous administration with an investigational product (drug or vaccine) within 
30 days (or as determined by [CONTACT_19970]) or [ADDRESS_1163220] dose of study intervention used in this study (whichever is longer) is prohibited.
All prescription and over-the-counter medications including vaccines taken by [CONTACT_88688] 30 days before study entry (considered prior treatment) will be recorded. Concomitant 
therapi[INVESTIGATOR_837521] 33 visit.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 55Permitted During the Study
All participants may receive supportive therapy for COVID-19, in addition to study 
intervention, unless listed as prohibited medication (see Appendix 9 ) or as defined in Section 
5.2. Supportive therapy for symptom management may include antipyretics, analgesics,antitussives and anti-emetics.
All participants may receive locally available mAb treatment, direct-acting antiviral 
treatment for SARS-CoV-2 (eg, remdesivir, molnupi[INVESTIGATOR_42654]), or convalescent COVID-[ADDRESS_1163221]-acting SARS-CoV-2 antiviral during drug dosing period, study drug (PF-07817883 or placebo) should be discontinued (refer to Section 7.1 ).
Prohibited During the Study
If participants require treatment with another antiviral as part of SoC, they will be able to do 
so, with the exception of PAXLOVID which is contraindicated to be administered concurrently with the study intervention due to DDI risk. The concomitant use of PAXLOVID is not permitted due to overlappi[INVESTIGATOR_837522]-07817883. If the participant needs to receive a direct-acting SARS-CoV-2 antiviral during drug dosing period, study drug (PF-07817883 or placebo) should be discontinued (refer to Section 7.1 ). COVID-19 vaccinations are permitted 
after the Day 33 visit.
PF-07817883 is primarily metabolized by [CONTACT_097]3A4. Therefore, concomitant use of any 
medications or substances that are moderate to strong inducers or inhibitors of CYP3A4 are prohibited within 28 days or 5 half-lives (whichever is longer) prior to dosing of study intervention and during study treatment.
A non-exhaustive list of prohibited and precautionary medications is provided in Appendix 9.
If a medication is not listed, it should not automatically be assumed it is safe to co-
administer. Appropriately qualified site staff will review all concomitant medications before the first dose of study intervention is administered to determine if they are strong inducers ofCYP3A4 and thus should be prohibited.
6.9.1. Rescue Medicine
Standard medical supportive care may be provided to manage AEs.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 567. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionIt may be necessary for a participant to permanently discontinue study intervention. Reasons 
for permanent discontinuation of study intervention include the following:
!AE of Grade 3 severity or greater and considered by [CONTACT_837547];
!SAE considered by [CONTACT_837547];
!Requirement for prohibited concomitant medication;
!Death;
!Pregnancy;
!Study terminated by [CONTACT_3211];
!Withdrawal by [CONTACT_837548];
!Miss more than 2 consecutive doses of study intervention.
!If post-screening eGFR is <30 mL/min/1.73m
2the participant will be instructed to 
discontinue any remaining study intervention doses as soon as study staff become aware of the eGFR results.
!Receipt of locally available concomitant, non-prohibited, direct-acting antiviral therapy for SARS-CoV-2.
In the event a participant is hospi[INVESTIGATOR_057], study intervention may continue to be administered, as feasible, and based on medical judgement of the investigator.
Discontinuation of study intervention does not represent withdrawal from the study. If study 
intervention is permanently discontinued, the participant should remain in the study to be evaluated for all subsequent scheduled assessments. See the SoA for data to be collected at 
the time of discontinuation of study intervention and follow-up for any further evaluations that need to be completed.
In the event of discontinuation of study intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further receipt of study intervention or also from study procedures, further study follow-up, and/or future collection of additional information.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 577.1.1. Potential Cases of Acute Kidney Injury
Participants exposed to IMP demonstrating transient or sustained increase in Screat (with 
decrease in Screat-based eGFR or eCrCL require expedited evaluation to differentiate AKI from DICI. DICI is defined as transporter-mediated effect related to altered renal tubular creatinine handling without histological injury.
Differentiating Acute Kidney Injury from DICI: AKI may be due to one or more types of injury, including DIKI. Differentiation of DIKI 
from other causes of AKI and from DICI may require clinical, radiographic, histopathologic, 
and laboratory assessments, as well as nephrology consultation.
Both AKI (including DIKI) and DICI are associated with (i) confirmed Screat increase 
≥0.3 mg/dL ( ≥26.5 μmol/L) within 48 hours OR (ii) confirmed Screat increase ≥1.5 times 
baseline (known or suspected to have occurred within the prior 7 days). Only AKI (including DIKI) is associated with 
!(i) simultaneous, confirmed serum cystatin C (Scys) increase and confirmed Screat 
increase OR (ii) confirmed albuminuria increase (see Appendix 7 for Grades A1 to A3 
quantitation) OR (iii) urine volume <0.5 mL/kg/h for 6 consecutive hours.  
!AKI is associated with decrease in Screat-based eGFR and combined Screat-Scys-based eGFR (when available).
Regardless of the presence or absence of increase in Screat, DIKI and other causes of AKImay be suspected if either there is (i) new-onset or worsening albuminuria or proteinuria are detected or (ii) urine volume (if measured) is <0.5 mL/kg/h for 6 consecutive hours.
Only DICI is associated with:
!Confirmed Screat increase without confirmed increase in reflex Scys AND confirmed 
Screat-based eGFR decrease without confirmed combined Screat-Scys-based eGFR decrease.
The participant should return to the site for evaluation as soon as possible, preferably within 48 hours of awareness of the abnormal results. Evaluation should include physical examination, laboratory tests, detailed medical and surgical history, review of all medications (including recreational drugs and supplements [herbal]), family history, sexual history, travel history, blood transfusion, and potential occupational exposure to chemicals. If appropriate, nephrology consultation may be recommended to facilitate differentiation of renal parenchymal disease, pre-renal azotemia, and post-renal obstruction. All confirmed cases of clinically relevant decrease in kidney function should be considered potential cases of DIKI if no other reason for the kidney function abnormalities has been found.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 587.1.2. Liver Injury
Please refer to Appendix 6 for suggested actions and follow-up assessments.
7.1.3. ECG ChangesA participant who meets either bulleted criteria based on the average of triplicate ECG 
readings will be withdrawn from the study intervention. 
!QTcF >500 ms;
!Change from baseline: QTcF >60 ms and QTcF > 450 ms.
Please refer to Section 8.3.5 for suggested actions and follow up assessments. If a clinically 
significant finding is identified (including, but not limited to, changes from baseline in QTcFafter enrollment), the investigator or qualified designee will determine if the participant can continue in the study and if any change in participant management is needed. This review of the ECG printed at the time of collection must be documented. Any new clinically relevant finding should be reported as an AE.
7.2. Participant Discontinuation/Withdrawal From the Study
A participant may withdraw from the study at any time at their own request. Reasons for 
discontinuation from the study include the following:
!Refused further study procedures;
!Lost to follow-up;
!Death;
!Study terminated by [CONTACT_3211];
!Investigator’s decision;
!Pregnancy.
At the time of discontinuing from the study, if possible, an early discontinuation visit should be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed.
The early discontinuation visit applies only to participants who are enrolled/randomized and 
then are prematurely withdrawn from the study. Participants should be questioned regarding their reason for withdrawal.
If a participant withdraws from the study, they may request destruction of any remaining 
samples taken and not tested, and the investigator must document any such requests in the site study records and notify the sponsor accordingly.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 59If the participant withdraws from the study and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations will be performed and no additional data will be collected. The sponsor may retain and continue to use any data collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent
Participants who request to discontinue receipt of study intervention will remain in the study 
and must continue to be followed for protocol-specified follow-up procedures. The only exception to this is when a participant specifically withdraws consent for any further contact [CONTACT_219879]. Participants should notify the investigator in writing of the decision to withdraw consent from future follow-up, whenever possible. The withdrawal of consent should be explained in detail in the medical records by [CONTACT_093], as to whether the withdrawal is only from further receipt of study intervention or also from study procedures and/or posttreatment study follow-up, and entered on the appropriate CRF page. In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.
7.3. Lost to Follow-Up 
A participant will be considered lost to follow-up if the participant repeatedly fails to return 
for scheduled visits and is unable to be contact[CONTACT_9298].
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:
!The site must attempt to contact [CONTACT_185610]. Counsel the participant on the importance of maintaining the assigned visit schedule, and ascertain whether the participant wishes to and/or should continue in the study;
!Before a participant is deemed lost to follow-up, the investigator or designee must make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_13140]’s medical record;
!Should the participant continue to be unreachable, the participant will be considered to have withdrawn from the study. 
8. STUDY ASSESSMENTS AND PROCEDURES
8.1. Administrative and Baseline ProceduresThe investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any study-specific procedures.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163222] reasons for screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline purposes provided the procedures met the protocol-specified criteria and were performed within the time frame defined in the SoA.
In the event a participant is hospi[INVESTIGATOR_057], study assessments should be performed as feasible. Procedures not performed due to hospi[INVESTIGATOR_837523].
Every effort should be made to ensure that protocol-required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that make it unfeasible to perform the test. In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant. When a protocol-required test cannot be performed, the investigator will document the reason for the missed test and any corrective and preventive actions that they have taken to ensure that required processes are adhered to as soon as possible. The study team must be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_22819].
The total blood sampling volume for individual participants in this study is approximately 
[ADDRESS_1163223] 2 individuals who can be 
contact[CONTACT_837549] (repeat/update as090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 61needed) at the times indicated on the SoA. Secondary contacts may be used to determine if a 
participant is lost to follow-up and/or vital status check (whether the participant is alive or 
dead).
8.1.2. Telehealth Visits
Telehealth visits may be used to assess participant safety and collect data points. Telehealth 
includes the exchange of healthcare information and services via telecommunication technologies (eg, audio, video, videoconferencing software) remotely, allowing the participant and the investigator to communicate on aspects of clinical care, including medical advice, reminders, education, and safety monitoring. The following assessments must be performed during a telehealth visit (see the SoA):
!Review and record study intervention(s), including compliance and missed doses.
!Review and record any AEs and SAEs since the last contact. Refer to Section 8.4.
!Review and record any new concomitant medications or changes in concomitant medications since the last contact.
!Review and record contraceptive method and results of pregnancy testing. Confirm that the participant is adhering to the contraception method(s) required in the protocol. Refer to Appendix 4 .
!Confirm the participant has completed the COVID-[ADDRESS_1163224] daily COVID-19 signs and symptoms, and other PRO assessments in the study diary.
Participants will receive daily reminders to complete entries on their own as specified in the 
SoA. The diary should be completed at approximately the same time every day. Staff will 
review the participant’s study diary online as specified in the SoA.
The diary allows recording of these assessments only within a fixed time window (eg, 24 hours), thus providing an accurate representation of the participant’s experience at 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163225]-party vendor, where they will be available for review by [CONTACT_837550]-based portal.
8.2.2. COVID-19-Related Medical Visit Details
Details of participants’ COVID-19-related medical visits (ie, hospi[INVESTIGATOR_059], practitioner’s
office, home healthcare services, telemedicine, urgent care, emergency room ≤24 hours, 
extended care facility stay) will be collected during study visits, including level of care (eg,ICU status), dates of utilization, and admission and discharge dates, as applicable. Whether medical visits are considered COVID-19-related will be determined by [CONTACT_093], for all outpatient and inpatients visits.
Hospi[INVESTIGATOR_31561] >24 hours of acute care, in a hospi[INVESTIGATOR_295362], including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19 during the COVID-19 pandemic. This includes specialized acute medical care unit within an assisted living facility or nursing home. This does not include hospi[INVESTIGATOR_295363]/or clinical trial execution.
8.2.3. Daily Signs and Symptoms of COVID-19
On Day 1, participants will complete the study diary before receiving study intervention. 
Participant assessment of COVID-19-related symptoms should be recorded at approximately the same time each day as specified in the SoA and described in Section 8.2.1 .
COVID-19-related symptoms will be evaluated in accordance with FDA guidelines (Appendix 10 ).
13Participants will record a daily severity rating of their symptom severity 
over the past 24 hours based on a 4-point scale in which 0 is reported if no symptoms were present; 1 if mild; 2 if moderate; and 3 if severe.
Vomiting and diarrhea will each be rated on a 4-point frequency scale where 0 is reported for 
no occurrence, 1 for 1 to 2 times, 2 for 3 to 4 times, and 3 for 5 or greater. 
Sense of smell and sense of taste will each be rated on a 3-point Likert scale where 0 is 
reported if the sense of smell/taste was the same as usual, 1 if the sense of smell/taste was 
less than usual, and 2 for no sense of smell/taste.
Five additional COVID-19 daily symptom diary items are included in the revised study 
diary: 1) Shortness of breath (difficulty breathing) while resting, 2) Shortness of breath (difficulty breathing) while physically active*, 3) Chest pain, 4) Low energy or tiredness after physical activity*, and 5) Difficulty concentrating. The response options for these questions are: None = 0, Mild = 1, Moderate = 2, or Severe = 3, and *I did not perform physical activity = 0 where applicable.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 638.2.4. Oxygen Support Details 
Type of oxygen support (eg, oxygen supplementation received at home, mechanical 
ventilation received in hospi[INVESTIGATOR_307]) will be collected.
8.2.5. Global Impression Questions
Three questions will be included in the ePRO to assess patient-reported global impression 
items a) return to usual health; b) return to usual activities; and c) overall COVID-19-related symptoms:
13
!In the past [ADDRESS_1163226] you returned to your usual health (before your COVID-19 illness)? Yes or No.
!In the past [ADDRESS_1163227] you returned to your usual activities (before your COVID-19 illness)? Yes or No.
!In the past [ADDRESS_1163228]? None, Mild, Moderate, or Severe.
The following three anchor items will also be included in the ePRO:
!Fatigue:
Please choose the response below that best describes the severity of your physical 
fatigue (ie, weakness, tiredness, lack of energy) over the past 7 days: None, Mild, Moderate, Severe or Very severe.
!Shortness of Breath:
Please choose the response below that best describes the severity of your shortness of 
breath (difficulty breathing) over the past 7 days: None, Mild, Moderate, Severe or Very severe.
!Cognitive Function:
Please choose the response below that best describes the severity of your difficulty 
concentrating over the past 7 days: None, Mild, Moderate, Severe or Very severe.
8.3. Safety Assessments
Planned time points for all safety assessments are provided in the SoA. Unscheduled safety 
measurements may be obtained at any time during the study to assess any perceived safety 
issues.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 648.3.1. Medical History
Medical history in addition to COVID-19 disease history and demographics will be collected 
at screening. Smoking status will be collected. Complete medication history of all prescription or nonprescription drugs (including vaccinations), and dietary and herbal supplements taken within [ADDRESS_1163229] dose will also be collected.
8.3.2. Height and Weight
Height and weight will also be measured and recorded at screening. Height may be self-
reported.
8.3.3. Targeted Physical Examinations
Physical examinations to be completed before administration of study intervention.
A targeted physical examination will include, at a minimum, cardiopulmonary assessments. 
Investigators should pay special attention to any previously identified or new AE/targeted condition that the participant has experienced.
Physical examination findings collected during the study will be considered source data and 
will not be required to be reported, unless otherwise noted. Any untoward physical examination findings that are identified during the active collection period and meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.4.[ADDRESS_1163230] vital sign findings that are identified during the active collection period and 
meet the definition of an AE or SAE ( Appendix 3) must be reported according to the 
processes in Sections 8.4.[ADDRESS_1163231] for the 
participant in a quiet setting without distractions (eg, television, cell phones).
Vital signs are to be taken before blood collection for laboratory tests.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page [IP_ADDRESS]. Blood Pressure and Pulse Rate
BP and PR measurements will be assessed with the participant, preferably in the supi[INVESTIGATOR_770389] a completely automated device. It is recommended that the same position should be used for a participant throughout the study duration. Manual techniques will be used only if an automated device is not available.
[IP_ADDRESS]. Temperature and Respi[INVESTIGATOR_837524], and respi[INVESTIGATOR_697], will be assessed.
[IP_ADDRESS]. Oxygen Saturation Level
Oxygen saturation level will be assessed as part of the vital signs assessment.
8.3.5. Electrocardiograms
Standard 12-lead ECGs utilizing limb leads (with a 10-second rhythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that
automatically calculates the HR and measures PR interval, QT interval, QTcF, and QRS complex. If an ECG cannot be obtained on Day 10, it must be collected at Day 14. An ECG should be obtained for a participant having an ET visit before Day 14. Alternative lead placement methodology using torso leads (eg, Mason-Likar) should not be used given the potential risk of discrepancies with ECGs acquired using standard limb lead placement. Post-dose ECGs should be performed within [ADDRESS_1163232] 5 minutes in a supi[INVESTIGATOR_2547]. Triplicate 12-lead ECGs obtained at a minimum at baseline/Day 1, should be obtained approximately 2 to 4 minutes apart.
ECG data may be submitted to a central laboratory for measurement. The final ECG report 
from the central laboratory should be maintained in the participant’s source documentation and be the final interpretation of the ECG recording. Any clinically significant changes from the baseline/Day 1 ECG may potentially be AEs ( Appendix 8 ) and should be evaluated 
further, as clinically warranted.
If a) a post-dose QTcF interval remains ≥60 ms from the baseline andis >450 ms; or b) an 
absolute QTcF value is ≥500 ms for any scheduled ECG for greater than 4 hours (or sooner,
at the discretion of the investigator); or c) QTcF values get progressively longer, the 
participant should undergo continuous ECG monitoring.
A cardiologist may be consulted if QTcF values do not return to less than the criteria listed 
above after 8 hours of monitoring (or sooner, at the discretion of the investigator).
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the same positions each time in order to achieve precise ECG recordings. If a machine-read QTc value is prolonged, as defined above, repeat measurements may not be necessary if a 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 66qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix [ADDRESS_1163233] findings are those that are not associated with the underlying disease, unless judged by [CONTACT_19448]'s condition.
All laboratory tests with values considered clinically significant and abnormal during 
participation in the study or within [ADDRESS_1163234] dose of study intervention should be repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_219883].
If such values do not return to normal/baseline within a period of time judged reasonable by 
[CONTACT_093], the etiology should be identified and the sponsor notified.
See Appendix [ADDRESS_1163235] abnormalities.[IP_ADDRESS]. Alternative Facilities for Clinical Safety Laboratory Assessment
Not applicable.
8.3.7. Pregnancy Testing
A serum or urine pregnancy test is required at screening. Following screening, pregnancy 
tests may be urine or serum tests, and must have a sensitivity of at least 25 mIU/mL. Pregnancy tests will be performed in WOCBP at the times listed in the SoA. Following a 
negative pregnancy test result at screening, appropriate contraception must be commenced and a second negative pregnancy test result will be required at the baseline visit prior to the 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 67participant’s receiving the study intervention. Pregnancy tests will also be done whenever 1 
menstrual cycle is missed during the active treatment period (or when potential pregnancy is otherwise suspected) and at the end of the study. Pregnancy tests may also be repeated if requested by [CONTACT_1202]/ECs or if required by [CONTACT_427]. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded if the serum pregnancy result is positive.
[IP_ADDRESS]. At-Home Pregnancy Testing
If a participant requiring pregnancy testing cannot visit a local laboratory, a home urine 
pregnancy testing kit with a sensitivity of at least 25 mIU/mL may be used by [CONTACT_22860], if compliant with local regulatory requirements. The pregnancy test outcome should be documented in the participant’s source documents/medical records and relevant data recorded on the CRF. If the pregnancy test is positive, the EDP should be reported ( Section [IP_ADDRESS] ). Confirm that the participant is adhering to the contraception 
method(s) required in the protocol.
[IP_ADDRESS]. Evaluation for Menopause
FSH is to be performed locally in female participants <[ADDRESS_1163236] result confirms postmenopausal status prior to dosing.
8.3.8. Adjunctive Therapeutic Procedures
Adjunctive therapeutic procedures will be recorded as specified in the SoA. Therapeutic 
procedures such as imaging, supplemental oxygen support (eg, CPAP) and transfusions
should be recorded.
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs may arise from symptoms or other complaints reported to the investigator by [CONTACT_2416] (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative), or they may arise from clinical findings of the investigator or other healthcare providers (clinical signs, test results, etc).
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue and obtain adequate information both to determine the outcome and to assess whether the event meets the criteria for classification as an SAE or caused the participant to discontinue the study intervention (see Section 7.1 ).090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 68During the active collection period as described in Section 8.4.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may be requested by [CONTACT_22835]-up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, which is obtained before undergoing any study-related procedure and/or receiving study intervention, through and including a minimum of [ADDRESS_1163237] SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in
Section 8.4.[ADDRESS_1163238] SAE Report Form immediately upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any updated SAE data to the sponsor within 24 hours of its being available.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page [IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.4.[ADDRESS_1163239] to the CRF 
requirements as described in Section 5.4 .
8.4.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.
8.4.3. Follow-Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and obtain adequate information until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3 ).
In general, follow-up information will include a description of the event in sufficient detail to allow for a complete medical assessment of the case and independent determination of possible causality. Any information relevant to the event, such as concomitant medications and illnesses, must be provided. In the case of a participant death, a summary of available autopsy findings must be submitted as soon as possible to [COMPANY_007] Safety. 
Further information on follow-up procedures is provided in Appendix [ADDRESS_1163240] the safety of participants and the safety of a study intervention under clinical investigation are met.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 70The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, IRBs/ECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the study and will notify the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental exposure include healthcare providers, family members, and others who may be exposed. An environmental exposure may include EDP, EDB, and occupational exposure.
Any such exposures to the study intervention under study are reportable to [COMPANY_007] Safety 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:
!A female participant is found to be pregnant while receiving or after discontinuing 
study intervention.
!A male participant who is receiving or has discontinued study intervention inseminates a female partner.
!A female nonparticipant is found to be pregnant while being exposed or having been exposed to study intervention because of environmental exposure. Below are examples of environmental EDP:
!A female family member or healthcare provider reports that she is pregnant after 
having been exposed to the study intervention by [CONTACT_78262].
!A male family member or healthcare provider who has been exposed to the study intervention by [CONTACT_837551].
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The initial information submitted 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 71should include the anticipated date of delivery (see below for information related to 
termination of pregnancy). 
!If EDP occurs in a participant/participant’s partner, the investigator must report this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP Supplemental Form, regardless of whether an SAE has occurred. Details of the pregnancy will be collected after the start of study intervention and until a minimum of [ADDRESS_1163241] administration of study intervention.
!If EDP occurs in the setting of environmental exposure, the investigator must report information to [COMPANY_007] Safety using the CT SAE Report Form and EDP Supplemental Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file.
Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify [COMPANY_007] Safety of the outcome as a follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by [CONTACT_4692] (unlesspreprocedure test findings are conclusive for a congenital anomaly and the findings are reported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly in a live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to [COMPANY_007] Safety as SAEs follows: 
!Spontaneous abortion including miscarriage and missed abortion should be reported as an SAE;
!Neonatal deaths that occur within [ADDRESS_1163242] to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study intervention. 
Additional information regarding the EDP may be requested by [CONTACT_456]. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 72the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An EDB occurs if:
!A female participant is found to be breastfeeding while receiving or after
discontinuing study intervention.
!A female nonparticipant is found to be breastfeeding while being exposed or having been exposed to study intervention (ie, environmental exposure). An example of environmental EDB is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by[CONTACT_78262].
The investigator must report EDB to [COMPANY_007] Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The information must be reported using the CT SAE Report Form. When EDB occurs in the setting of environmental exposure, the exposure information does not pertain to the participant enrolled in the study, so the information is not recorded on a CRF. However, a copy of the completed CT SAE Report Form is maintained in the investigator site file.
An EDB report is not created when a [COMPANY_007] drug specifically approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use. However, if the infant experiences an SAE associated with such a drug, the SAE is reported together with the EDB.
[IP_ADDRESS]. Occupational Exposure
The investigator must report any instance of occupational exposure to [COMPANY_007] Safety within 
24 hours of the investigator’s awareness using the CT SAE Report Form, regardless of whether there is an associated SAE. Since the information about the occupational exposuredoes not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form must be maintained in the investigator site file.
8.4.6. Cardiovascular and Death Events
Not applicable.
8.4.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.4.8. Adverse Events of Special Interest
Not applicable.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page [IP_ADDRESS]. Lack of Efficacy
The investigator must report signs, symptoms, and/or clinical sequelae resulting from lack of 
efficacy. Lack of efficacy or failure of expected pharmacological action is reportable to [COMPANY_007] Safety only if associated with an SAE .
8.4.9. Medical Device Deficiencies
Not applicable.
8.4.10. Medication Errors
Medication errors may result from the administration or consumption of the study 
intervention by [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.
Medication errors are recorded and reported as follows:
Recorded on the 
Medication Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the medication errorOnly if associated with an 
SAE
Medication errors include:
!Medication errors involving participant exposure to the study intervention;
!Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant.
!The administration of expi[INVESTIGATOR_336249];
!The administration of an incorrect study intervention;
!The administration of an incorrect dosage;
!The administration of study intervention that has undergone temperature excursion from the specified storage range, unless it is determined by [CONTACT_336271].
!The administration of study intervention consistent with the medication error descriptions in Section 6.5 .
Such medication errors occurring to a study participant are to be captured on the medication error page of the CRF, which is a specific version of the AE page.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 74Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.
In the event of a medication dosing error, the sponsor should be notified within [ADDRESS_1163243] SAE Report 
Form only when associated with an SAE.
8.5. Pharmacokinetics
Blood samples of approximately 4 mL, to provide a minimum of 1.5 mL of plasma, will be 
collected for measurement of plasma concentrations of PF-07817883 as specified in the SoA.
Prior to centrifugation a 0.1 mL portion of the 4 mL of blood collected will be aliquoted for the purpose of determining the blood to plasma PF-07817883 concentration ratio at each time point as specified in the SoA. In addition, approximately 0.1 mL of blood will be collected 
using a micro-sampling device (TASSO M20) for the measurement of plasma concentrations of PF-07817883 at each time point as specified in the SoA. Instructions for the collection and 
handling of biological samples will be provided in the laboratory manual or by [CONTACT_456].The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. 
Samples will be used to evaluate the PK of PF-07817883. Each plasma sample will be 
divided into 2 aliquot(s) (1 each for PK, other analyses, etc). Samples collected for analyses of PF-07817883 plasma concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, or for other internal exploratory purposes.
Genetic analyses will not be performed on these plasma or whole blood samples unless 
consent for this was included in the informed consent. Participant confidentiality will be maintained.
Samples collected for measurement of plasma or whole blood concentrations of 
PF-[ADDRESS_1163244] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_19944]), including any actions taken, must be documented and reported to the sponsor. On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163245] 
be documented and approved by [CONTACT_487229], but will not constitute a protocol amendment. The IRB/EC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICD.
8.6. Genetics
8.6.1. Specified GeneticsSpecified genetic analyses are not evaluated in this study.
8.6.2. Retained Research Samples for Genetics
A 4 mL blood sample optimized for DNA isolation Prep D1 will be collected according to the 
SoA, as local regulations and IRBs/ECs allow, and if the participant signs the optional 
consent form.
Retained Research Samples may be used for research related to the study intervention(s) and 
COVID-19. Genes and other analytes (eg, proteins, RNA, nondrug metabolites) may be studied using the retained samples. 
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in the laboratory manual.8.7. Biomarkers
Collection of samples for biomarker research is also part of this study. 
The following samples for biomarker research are required and will be collected from all 
participants in this study as specified in the SoA:
!NP samples will be collected to measure SARS-CoV-2 viral RNA level by [CONTACT_937]-PCR.
!Residual NP viral RNA level samples may be used for SARS-CoV-2 viral sequencing.
!Residual NP viral RNA level samples may be used for SARS-CoV-2 infectivity assays and phenotypic analyses.
!10 mL blood optimized for plasma may be utilized for proteomics and immunologicstudies.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163246] kit that is authorized by [CONTACT_104222] a nasal specimen collected within 2 days prior to randomization is required.
8.7.2. Specified Gene Expression (RNA) Research 
Specified gene expression (RNA) research is not included in this study.
8.7.3. Specified Protein Research 
Blood will be collected for plasma biomarkers as specified in the SoA and may be used for
proteomics and molecular and immunologic studies. Residuals of all samples may be banked 
for future research. Storage and shippi[INVESTIGATOR_768774].
8.7.4. Specified Metabolomic Research
Specified metabolomic research is not included in this study.
8.7.5. Viral RNA Level Assessments
A NP sample will be collected per the SoA, and may be analyzed to measure SARS-CoV-[ADDRESS_1163247] will not be used to determine study eligibility. NP samples will be collected by [CONTACT_837552]-person visit.
If a participant is symptomatic due to COVID-19 infection at the Day 21 visit then a Day 33 
NP sample should be collected.
If COVID-19 symptom worsening or recurrence occurs after completion of the 5-day
treatment with study drug (ie, through Day 33), participants may subsequently attend a site for an unscheduled follow-up visit and should have NP sample collected to measure SARS-CoV-[ADDRESS_1163248] molecular or genetic analysis.
Residuals of all samples may be banked for future research. Storage and shippi[INVESTIGATOR_837525].090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 778.7.6. Retained Research Samples for Biomarkers
These Retained Research Samples will be collected in this study if the participant signs the 
optional consent form:
!5 mL whole blood optimized for serum Prep B2.5.
!2.5 ml whole blood optimized for RNA Prep R1.
Retained Research Samples will be collected in this study as local regulations and IRB/ECs allow according to the SoA.
Retained Research Samples may be used for research related to the study intervention(s) and
COVID-19. Genes and other analytes (eg, proteins, RNA, nondrug metabolites) may bestudied using the retained samples.
See Appendix 5 for information regarding genetic research. Details on processes for
collection and shipment of these samples can be found in the laboratory manual.8.8. Immunogenicity Assessments
Immunogenicity assessments are not applicable to this study.
8.9. Health Economics
Health economics/medical resource utilization and health economics parameters will be 
evaluated in this study ( Section 8.2.2 and Section 8.2.3).
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in the SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypothesis
The primary hypothesis is to test whether or not there is a difference in mean change of 
SARS-CoV-2 RNA level from baseline to Day 5 between the PF-07817883 dose groups and the placebo group using the Bayesian dose-response model (or otherwise as specified in Section [IP_ADDRESS]):
Null hypothesis: H
0             −         =0
Alternative hypothesis: H a             −         <0
Where             and          are mean change of SARS-CoV-2 RNA level from 
baseline to Day 5 for each PF-07817883 dose groups and placebo group.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 789.1.1. Estimands
[IP_ADDRESS]. Primary EstimandE1(primary analysis estimand): The estimand is the difference between the PF-[ADDRESS_1163249] SARS-CoV-2 RNA level ≥4l o g
10copi[INVESTIGATOR_014]/mL at baseline. This analysis
will exclude data after use of prohibited COVID-19 medications and study treatment discontinuation.
E2(estimand for supplementary analyses): The estimand is the difference between the 
PF-07817883 dose groups and placebo in mean change from baseline in SARS-CoV-2 RNA 
level in NP samples in the population of non-hospi[INVESTIGATOR_057], symptomatic, adult participants with COVID-19. This will exclude data after use of prohibited COVID-19 medications and study treatment discontinuation.
The E2 estimand will be applied to change from baseline in SARS-CoV-2 RNA level on 
Days 3, 5, 10 and 14 for the supplementary analysis.
Note that for E1 and E2, partial participant data accumulated prior to use of prohibited 
COVID-19 medications or treatment discontinuation is included in the analysis.
[IP_ADDRESS]. Secondary Estimands
The E1 estimand will be applied to change from baseline in SARS-CoV-2 RNA level on 
Days 3, 10 and 14.
9.1.2. Multiplicity AdjustmentNot applicable.
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis Set Description
Enrolled "Enrolled" means a participant's, or their legally authorized
representative’s, agreement to participate in a clinical 
study following completion of the informed consent process and randomization to study intervention. A participant will be considered enrolled if the informed consent is not withdrawn prior to participating in any study activity after screening. Potential participants who are screened for the purpose of determining eligibility for the study, but do not participate in the study, are not considered enrolled, unless otherwise specified by [CONTACT_760].090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163250] SARS-CoV-2 RNA 
level≥4l o g 10copi[INVESTIGATOR_014]/mL at baseline.
Participants will be analyzed according to the study intervention to which they were randomized.
9.3. Statistical Analyses
The SAP will be developed and finalized before any analyses are performed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data.Further analysis details will be included in SAP. This section is a summary of the planned statistical analyses of the primary and secondary endpoints.
9.3.1. General Considerations
Descriptive statistics for all efficacy endpoints by [CONTACT_547730].
The number of participants screened will be reported. The number of participants 
randomized to the double-blind treatment phase, completing the study drug administration, completing the study, and discontinued the study will be summarized from the FAS for each treatment group.
Baseline demographic and other characteristics will be tabulated for the FAS and 
summarized by [CONTACT_1570]. Quantitative variables will be described by [CONTACT_262309] (mean, standard deviation, minimum, and maximum), and qualitative variables will be summarized by [CONTACT_837553] (with the corresponding sample sizes).090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 80For continuous endpoints, an MMRM model will be used to analyze change from baseline 
outcomes. Estimated mean differences between treatments and their respective 80% CI and p-values will be calculated.
Binary endpoints will be summarized with the number and percent of participants satisfying 
the endpoint.
For categorical endpoints, proportion of participants for each category will be summarized 
for each treatment group.
For count endpoints, the total number of the events and average number of events will be 
summarized for each treatment group.
Time to event endpoints will be summarized graphically using Kaplan-Meier plots for each 
treatment group. 
9.3.2. Primary Endpoint(s)/Estimand(s) Analysis
[IP_ADDRESS]. Definition of Endpoint(s)The primary efficacy endpoint is the change in SARS-CoV-2 RNA level from baseline to 
Day 5 as measured in NP samples.
[IP_ADDRESS]. Main Analytical Approach
The primary analysis will utilize a Bayesian Emax model applied to the estimates from the 
MMRM analysis. 
Change from baseline in SARS-CoV-[ADDRESS_1163251] be analyzed using 
Estimand 1 and MMRM model (as per Section 9.3.1). The MMRM model will be fitted to the change from baseline at all post-treatment timepoints up to Day 5 using MFAS with fixed effects including treatment, time, interaction of time by [CONTACT_3148], and baseline SARS-CoV-2 RNA level. Further specification of the MMRM model will be provided in the SAP. LSmeans (and 80% CIs and p-values) will be summarized.
A Bayesian Emax model will then be fitted to the Day 5 LSmeans and SEs from the MMRM 
analysis. Non-informative prior distributions for the placebo ( E
0), the difference in response 
(difTarget ) between the highest dose (600 mg q12h) and placebo, and the residual standard 
deviation ( sigma).
The fitted curve will be graphically displayed with 80% credible bands. The posterior medians and 80% credible intervals (10
thand 90thpercentiles of the relevant posterior 
distribution) will be reported for each randomized dose (including placebo) and their differences relative to placebo. If the Bayesian Emax model cannot be fitted to the data, or the data do not support a dose-response, the model may be simplified, or the analysis may not be performed and the primary results for the study will be based on the MMRM results at Day 5. More details on how this will be assessed will be described in the SAP. No adjustments will be made for multiplicity in the MMRM model.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page [IP_ADDRESS]. Supplementary Analyses
The MMRM analysis and Bayesian Emax dose-response model described in Section [IP_ADDRESS]
will be repeated using the FAS instead of MFAS and use the E2 estimand strategy.
9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis
Details on the definitions and analyses of secondary endpoints will be described in the SAP. 
Secondary endpoints include:
!Change from baseline in SARS-CoV-2 RNA level on Days 3, 10 and 14.
!Incidence of TEAEs.
!Incidence of SAEs and AEs leading to discontinuations.
!Incidence of clinically significant abnormal laboratory values, vital signs, and ECGs.
No formal statistical analysis will be conducted on any of the safety data listed above.
9.3.4. Tertiary/Exploratory Endpoint(s) Analysis
Exploratory endpoints may not be reported in the CSR and may be reported separately.
Details on the definitions and analyses of the exploratory endpoints, if reported in the CSR,
will be described in the SAP or equivalent analysis plan.
9.3.5. Other Safety Analyses
All safety analyses will be performed on the Safety Analysis Set.
[IP_ADDRESS]. Electrocardiogram Analyses
Changes from baseline for the ECG parameters HR, QTcF, PR interval, and QRS complex
will be summarized by [CONTACT_22841]. The frequency of uncorrected QT values above 500 ms will be tabulated.
The number (%) of participants with maximum post-dose QTcF values and maximum 
increases from baseline in the following categories will be tabulated by [CONTACT_3148]: 
Safety QTcF Assessment
Degree of Prolongation Mild (ms) Moderate (ms) Severe (ms)
Abs value >450-480 >480-500 >500
Increase from baseline 30-60 >60
9.3.6. Other Analyses 
Pharmacogenomic or biomarker data from Retained Research Samples may be collected 
during or after the trial and retained for future analyses; the results of such analyses are not planned to be included in the CSR.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 829.4. Interim Analyses
A planned formal interim analysis for virological response and safety may be performed to 
assess SARS-CoV-2 RNA level after approximately 50% or more participants, ie, at least 114 participants with baseline SARS-CoV-2 RNA level ≥4 log
10copi[INVESTIGATOR_014]/mL, complete their 
study participation (including viral load assessment) through Day 5. The timing of the interim analysis is contingent on the recruitment rate.
Additional interim analysis may be performed for internal business decision-making or 
regulatory requests. Before any interim analyses are conducted, the final number and timings of interims, the details of the objectives, decision criteria, information dissemination plan, and method for maintaining the study blind as per [COMPANY_007]’s SOPs will be documented and approved in an IRC charter and interim analysis plan. The study team will remain blinded to all interim results.
Participants may be discontinued from the study intervention/study as a result of the interim 
analysis, as described in Section 7 .
9.5. Sample Size Determination
A sufficient number of participants will be screened to achieve a total of approximately 228 
participants, with participants randomly assigned to PF-07817883 100, 300, or 600 mg q12hand placebo in approximately a 1:1:2:2 ratio. Assuming 20% of participants will discontinue study drug treatment or have a baseline SARS-CoV-2 RNA level <4 log
10copi[INVESTIGATOR_014]/mL,
approximately 180 participants (60 in each of PF-07817883 600 mg q12h and placebo, and 30 in each of PF-07817883 100 mg q12h and 300 mg q12h) with baseline SARS-CoV-2 
RNA level ≥ 4 log
10copi[INVESTIGATOR_014]/mL are expected to complete Day 5 of the study. Additional
participants may be randomized to ensure 180 participants with baseline SARS-CoV-2 RNA 
level ≥4 log 10copi[INVESTIGATOR_014]/mL who complete study drug treatment.
The sample size is based on the primary efficacy endpoint, change from baseline in SARS-
CoV-2 RNA leve l at Day 5.  
!
;15
!
.15
Based on the above, 180 participants with baseline SARS-CoV-2 RNA level ≥4l o g 10
copi[INVESTIGATOR_014]/mL who complete study drug treatment and 228 enrolled participants, in a 1:1:2:2 randomization ratio, gives acceptable operating characteristics for the study.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
CCI
CCI
CCI
CCI
CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163252] 1 concentration value is reported. PK concentrations will be summarized and presented with descriptive statistics. A population PK modeling may be performed with the concentration data from this study alone or combined with data from other studies. In addition, a relationship between exposures and efficacy/safety endpoints may be evaluated using population PK/PD approach. Any population analyses conducted will not be part of the CSR and may be reported separately.
9.6.1. Early PK/PD Unblinding Plan
If needed, a PK/PD unblinding plan will be in place prior to the start of the PK/PD 
unblinding in accordance with applicable [COMPANY_007] SOPs for releasing randomization codes and breaking the study blind.
Under this plan, a group of statisticians, data programmer, PK/PD data provider, PK/PD 
analyst and PK/PD support would be unblinded in order to initiate the building of statistical models of the PK, dose/response as well as exposure/response analysis models and conduct associated simulations. The aim of this work would be to facilitate a fuller interpretation of the study upon completion (at appropriate interim milestone). This group will not serve on the study team during the period of early unblinding. The unblinding may occur at an appropriate time as defined in the data blinding plan to allow sufficient time for PK/PD analyses. PK/PD modeling and simulation may be used at or after the first planned interim analysis to inform dose selection for subsequent studies. If performed, these activities will only impact decisions at the program level and not impact the conduct of the ongoing study.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 8410. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations10.1.1. Regulatory and Ethical ConsiderationsThis study will be conducted in accordance with the protocol and with the following:
!Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;
!Applicable ICH GCP guidelines;
!Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents (eg, advertisements) must be reviewed and approved by [CONTACT_456], submitted to an IRB/EC by [CONTACT_093], and reviewed and approved by [CONTACT_1201]/EC before the study is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.
Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to study participants.
The investigator will be responsible for the following:
!Providing written summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/EC;
!Notifying the IRB/EC of SAEs or other significant safety findings as required by [CONTACT_1744]/EC procedures;
!Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the IRB/EC, European regulation 
536/2014 for clinical studies, European Medical Device Regulation 2017/745 for clinical device research, and all other applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_22844], or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the study intervention, [COMPANY_007] should be informed immediately. 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163253], and of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator becomes aware of.
10.1.2. Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities.Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.
10.1.3. Informed Consent Process
The investigator or the investigator’s representative will explain the nature of the study, 
including the risks and benefits, to the participant or their legally authorized representative and answer all questions regarding the study. The participant or their legally authorized representative should be given sufficient time and opportunity to ask questions and to decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary. Participants or their legally 
authorized representative (if allowed by [CONTACT_427]) will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, privacy and data protection requirements, where applicable, and the IRB/EC or study center.
The investigator must ensure that each participant or their legally authorized representative is 
fully informed about the nature and objectives of the study, the sharing of data related to the study, and possible risks associated with participation, including the risks associated with the processing of the participant’s personal data. 
The participant or their legally authorized representative must be informed that their personal 
study-related data will be used by [CONTACT_10999]. The level of disclosure must also be explained to the participant or their legally authorized representative.
The participant or their legally authorized representative must be informed that their medical 
records may be examined by [CONTACT_837554], by [CONTACT_6667]/EC members, and by [CONTACT_6668].
The investigator further must ensure that each study participant or their legally authorized 
representative is fully informed about their right to access and correct their personal data and to withdraw consent for the processing of their personal data.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163254] current 
version of the IRB/EC-approved ICD(s) during their participation in the study as required per local regulations.
A copy of the ICD(s) must be provided to the participant or their legally authorized 
representative (if allowed by [CONTACT_427]).
10.1.4. Data Protection
All parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study site in encrypted electronic and/or paper
form and will be password protected or secured in a locked room to ensure that only authorized study staff have access. The study site will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster. In the event of a potential personal data breach, the study site will be responsible for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant-specific numerical code. Any participant records or data sets that are transferred to the sponsor will contain the numerical code; participant names will not be transferred. All other identifiable data transferred to the sponsor will be identified by [CONTACT_20007], participant-specific code. The study site will maintain a confidential list of participants who participated in the study, linking each participant’s numerical code to their actual identity and medical record ID. In case of data transfer, the sponsor will protect the confidentiality of participants’ personal data consistent with the clinical study agreement and applicable privacy laws.
Information technology systems used to collect, process, and store study-related data are 
secured by [CONTACT_336272], alteration, or unauthorized disclosure or access.
The sponsor maintains SOPs on how to respond in the event of unauthorized access, use, or 
disclosure of sponsor information or systems.
10.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee This study will use an IRC. The IRC is independent of the study team and includes only 
internal members. The IRC charter describes the role of the IRC in more detail.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 87The IRC will be responsible for ongoing monitoring of the safety of participants in the study 
according to the charter. The recommendations made by [CONTACT_837555]. [COMPANY_007] will communicate such decisions, which may include summaries of aggregate analyses of safety data, to regulatory authorities and investigators, as appropriate.
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT/CTIS, and/or www.pfizer.com, and other public registries and websites in accordance with applicable local laws/regulations. In addition, [COMPANY_007] reports study results outside of the requirements of local laws/regulations pursuant to its SOPs.
In all cases, study results are reported by [CONTACT_4715], accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]-sponsored interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product, regardless of the geographical location in which the study is conducted. These results are submitted for posting in accordance with the format and timelines set forth by [CONTACT_20008].
EudraCT/CTIS
[COMPANY_007] posts clinical trial results on EudraCT/CTIS for [COMPANY_007]-sponsored interventional studies 
in accordance with the format and timelines set forth by [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts CSR synopses and plain-language study results summaries on www.pfizer.com 
for [COMPANY_007]-sponsored interventional studies at the same time the corresponding study results are posted to www.clinicaltrials.gov. CSR synopses will have personally identifiable information anonymized.
Documents within marketing applications
[COMPANY_007] complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally identifiable information anonymized.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 88Data sharing
[COMPANY_007] provides researchers secure access to participant-level data or full CSRs for the 
purposes of “bona-fide scientific research” that contributes to the scientific understanding of the disease, target, or compound class. [COMPANY_007] will make data from these trials available [ADDRESS_1163255], including individuals requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_18027].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic form and are password protected to prevent access by [CONTACT_20011].
QTLs are predefined parameters that are monitored during the study. Important deviations 
from the QTLs and any remedial actions taken will be summarized in the CSR.
The investigator must permit study-related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source records and documents.This verification may also occur after study completion. It is important that the investigator(s) and their relevant personnel are available during the monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy, including definition of study-critical data items and 
processes (eg, risk-based initiatives in operations and quality such as risk management and mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on-site monitoring), are provided in the data management plan and monitoring plan maintained and utilized by [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163256] ensure that the records continue  to be stored securely for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_306891].
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate with the sponsor or its agents to prepare the investigator site for the inspection and will allow the sponsor or its agent, whenever feasible, to be present during the inspection. The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the participant’s medical records. The investigator will promptly provide copi[INVESTIGATOR_19946]. Before response submission to the regulatory authorities, the investigator will provide the sponsor or its agents with an opportunity to review and comment on responses to any such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.
Definition of what constitutes a source document and its origin can be found in the Source 
Document Locator, which is maintained by [CONTACT_456].
Description of the use of the computerized system is documented in the data management 
plan, which is maintained by [CONTACT_456].
The investigator must maintain accurate documentation (source record) that supports the 
information entered in the CRF.
The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP guidelines, and all applicable regulatory requirements.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163257] participant’s first visit.
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor, including (but not limited to) regulatory authority decision, change in opi[INVESTIGATOR_1100]/EC, or change in benefit-risk assessment. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time upon notification to the sponsor 
or designee/CRO if requested to do so by [CONTACT_22846]/EC or if such termination is required to protect the health of study participants.
Reasons for the early closure of a study site by [CONTACT_19711]:
!Failure of the investigator to comply with the protocol, the requirements of the IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP guidelines;
!Inadequate recruitment of participants by [CONTACT_093];
!Discontinuation of further study intervention development.
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the investigators, the ECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow-up.
Study termination is also provided for in the clinical study agreement. If there is any conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.10. Publication Policy
For multicenter trials, the primary publication will be a joint publication developed by [CONTACT_446992](s) of the study covering all study sites. The investigator agrees to refer to the primary publication in any subsequent publications. [COMPANY_007] will not provide any financial compensation for the investigator’s participation in the preparation of the primary congress abstract, poster, presentation, or primary manuscript for the study.
Investigators are free to publish individual center results that they deem to be clinically 
meaningful after publication of the overall results of the study or 12 months after primary 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.[ADDRESS_1163258] to the other 
requirements described in this section.
The investigator will provide [COMPANY_007] an opportunity to review any proposed publication or 
any other type of disclosure of the study results (collectively, “publication”) before it is submitted or otherwise disclosed and will submit all publications to [COMPANY_007] [ADDRESS_1163259], remove any previously undisclosed confidential information before disclosure, except for any study-intervention or [COMPANY_007]-related information necessary for the appropriate scientific presentation or understanding of the study results. For joint publications, should there be disagreement regarding interpretation and/or presentation of specific analysis results, resolution of, and responsibility for, such disagreements will be the collective responsibility of all authors of the publication.
For all publications relating to the study, the investigator and [COMPANY_007] will comply with 
recognized ethical standards concerning publications and authorship, including those established by [CONTACT_4717]. The investigator will disclose any relationship with [COMPANY_007] and any relevant potential conflicts of interest, including any financial or personal relationship with [COMPANY_007], in any publications. All authors will have access to the relevant statistical tables, figures, and reports (in their original format) required to develop the publication.
10.1.11. Sponsor’s Medically Qualified Individual 
The contact [CONTACT_1133]’s MQI for the study is documented in the study 
contact [CONTACT_219903]/study portal or other electronic system.
To facilitate access to their investigator and the sponsor’s MQI for study-related medical 
questions or problems from non-study healthcare professionals, participants are provided with an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and study intervention identifiers, (b) participant’s study identification number, (c) site emergency phone number active 24 hours/day, 7 days per week, and (d) [COMPANY_007] Call Center number.
The ECC is intended to augment, not replace, the established communication pathways 
between the participant and their investigator and site staff, and between the investigator and sponsor study team. The ECC is only to be used by [CONTACT_336274], as a means of reaching the investigator or site staff related to the care of a participant. The [COMPANY_007] Call Center number is to be used when the investigator and site staff are unavailable. The [COMPANY_007] Call Center number is not for use by [CONTACT_240875]; if a participant calls that number directly, they will be directed back to the investigator site.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 9210.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of 
the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 4. Protocol Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis OtheraAdditional Tests 
(Needed for Suspected
Hy’s Law or DIKI)
Hemoglobin
HematocritRBC countPlatelet countWBC count
Total neutrophils 
(Abs)Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)Lymphocytes 
(Abs)BUN or Urea 
Creatinine
b
Cystatin CeGFR (combined 
Scr+Scys)
GlucoseCalciumSodiumPotassiumChloride
Total CO
2 
(bicarbonate)
AST, ALTTotal bilirubinAlkaline phosphatase
Albumin
Total proteinLocal dipstick:
pHGlucose (qual)Protein (qual)Blood (qual)
Ketones
NitritesLeukocyte esterase
Laboratory:
Albumin (urine)
Creatinine (urine)Urine albumin to creatinine ratio (UACR)
Microscopy and 
culture
cFerritinD-dimerhs-CRPProcalcitoninLDH
CK
Haptoglobin
SARS-CoV-2 
serology (IgM, IgG)
d
At screening:
FSHe
Pregnancy test 
(βhCG)fHy’s LawAST, ALT Total bilirubinAlbumin Alkaline phosphatase 
Direct bilirubin
Indirect bilirubinCreatine kinaseGGTPT/INRTotal bile acids
Acetaminophen drug 
and/or protein adduct levels
DIKI
Cystatin C
eGFR
Albumin (urine)Creatinine (urine)Urine albumin to creatinine ratio (UACR)
a. For Day [ADDRESS_1163260] for the protocol unless serum testing is required by [CONTACT_18039]/EC. Serum or urine β-hCG for female participants of childbearing potential.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 9310.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting
10.3.1. Definition of AE
AE Definition
!An AE is any untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
!Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
Events Meeting the AE Definition
!Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator. Any abnormal laboratory test results that meet any of the conditions below must be recorded as an AE:
!Is associated with accompanying symptoms.
!Requires additional diagnostic testing or medical/surgical intervention.
!Leads to a change in study dosing (outside of any protocol-specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy.
!Exacerbation of a chronic or intermittent preexisting condition, including an 
increase in either frequency and/or intensity of the condition.
!New condition detected or diagnosed after study intervention administration, even 
though it may have been present before the start of the study.
!Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
!Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE or SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 94Events NOT Meeting the AE Definition
!Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_19448]’s condition.
!The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant’s condition.
!Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.
!Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
!Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a. Results in death
b. Is life-threatening
The term “life-threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically might have caused death if it were more severe.
c. Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually involving at least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 95d. Results in persistent or significant disability/incapacity
!The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
!This definition is not intended to include experiences of relatively minor medical significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle), that may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
e. Is a congenital anomaly/birth defect
f. Is a suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic 
or nonpathogenic
The event may be suspected from clinical symptoms or laboratory findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected transmission” and “transmission” are considered synonymous. These cases are considered unexpected and handled as serious expedited cases by [CONTACT_20020]. Such cases are also considered for reporting as product defects, if appropriate.
g. Other situations:
!Medical or scientific judgment should be exercised by [CONTACT_705130], such as significantmedical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.
!Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias orconvulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 9610.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During the Active 
Collection Period 
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on the CRF and for reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safety throughout the active collection period. These requirements are delineated for 3 types of events: (1) SAEs; (2) nonserious AEs; and (3) exposure to the study intervention under study during pregnancy or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be completed in a consistent manner. AEs should be recorded using concise medical terminology and the same AE term should be used on both the CRF and the CT SAE Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] Safety Within 24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study intervention under study during pregnancy or breastfeeding All AEs or SAEs associated with EDP or EDB
Note: Instances of EDP or 
EDB not associated with an AE or SAE are not captured in the CRFAll instances of EDP are reported (whether or not there is an associated SAE)*
All instances of EDB are 
reported (whether or not there is an associated SAE)**
Environmental or occupational exposure to the product under study to a nonparticipant (not involving EDP or EDB)None. Exposure to a study nonparticipant is not collected on the CRFThe exposure (whether or not there is an associated AE or SAE) must be reported***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to [COMPANY_007] 
Safety using the CT SAE Report Form and EDP Supplemental Form; if the EDP is associated with an 
SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report Form. 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form, which would also include details
of any SAE that might be associated with the EDB. 
*** Environmental or occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form. 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 97!When an AE or SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic reports) related to the event.
!The investigator will then record all relevant AE or SAE information in the CRF.
!It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT SAE Report Form/AE or SAE CRF page.
!There may be instances when copi[INVESTIGATOR_240802]. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_346246].
!The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories, which are based on the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
14, version 
2.1 (July 2017):
GRADE Clinical Description of Severity
1 MILD adverse event
2 MODERATE adverse event
3 SEVERE adverse event
4 POTENTIALLY LIFE-THREATENING event 
5 DEATH RELATED TO adverse event
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
!The investigator is obligated to assess the relationship between study intervention and each occurrence of each AE or SAE. The investigator will use clinical judgment to determine the relationship.
!A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 98!Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention administration, will be considered and investigated.
!The investigator will also consult the IB and/or product information, for marketed products, in their assessment.
!For each AE or SAE, the investigator must document in the medical notes that they 
have reviewed the AE or SAE and have provided an assessment of causality.
!There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor.
!The investigator may change their opi[INVESTIGATOR_9242]-up information and send an SAE follow-up report with the updated causality assessment.
!The causality assessment is one of the criteria used when determining regulatory reporting requirements.
!If the investigator does not know whether or not the study intervention caused the event, then the event will be handled as “related to study intervention” for reporting purposes, as defined by [CONTACT_456]. In addition, if the investigator determines that an SAE is associated with study procedures, the investigator must record this causal relationship in the source documents and CRF, and report such an assessment in the dedicated section of the CT SAE Report Form and in accordance with the SAE reporting requirements.
Follow-Up of AEs and SAEs
!The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically indicated or as requested by [CONTACT_103], to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other healthcare providers.
!If a participant dies during participation in the study or during a recognized follow-up period, the investigator will provide [COMPANY_007] Safety with a copy of any postmortem findings, including histopathology. 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 99!New or updated information will be recorded in the originally submitted 
documents.
!The investigator will submit any updated SAE data to the sponsor within [ADDRESS_1163261]
!The primary mechanism for reporting an SAE to [COMPANY_007] Safety will be the electronic DCT.
!If the electronic system is unavailable, then the site will use the paper SAE DCT(see next section) to report the event within 24 hours.
!The site will enter the SAE data into the electronic DCT (eg, eSAE or PSSA) or paper form (as applicable) as soon as the data become available.
!After the study is completed at a given site, the electronic DCT will be taken off-line to prevent the entry of new data or changes to existing data.
!If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic DCT has been taken off-line, 
then the site can report this information on a paper SAE form (see next section) or to [COMPANY_007] Safety by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via the CT SAE Report Form
!Facsimile transmission of the CT SAE Report Form is the preferred method to transmit this information to [COMPANY_007] Safety.
!In circumstances when the facsimile is not working, an alternative method should be used, eg, secured (Transport Layer Security) or password-protected email. If none of these methods can be used, notification by [CONTACT_9337] a copy of the CT SAE Report Form sent by [CONTACT_22855].
!Initial notification via telephone does not replace the need for the investigator to complete and sign the CT SAE Report Form pages within the designated reporting time frames.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page [ZIP_CODE].4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion CriteriaMale participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least [ADDRESS_1163262] dose of study intervention, which corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s):
!Refrain from donating sperm.
PLUS either :
!Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.
OR
!Must agree to use contraception/barrier as detailed below:
!Agree to use a male condom, and should also be advised of the benefit for a 
female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a WOCBP who is not currently pregnant.
!In addition to male condom use, a highly effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly 
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1 ) and specify 
the reproductive requirements for including female participants. Refer to Section 10.4.[ADDRESS_1163263] of contraceptive methods permitted in the study. 
A female participant is eligible to participate if she (a) is not pregnant or breastfeeding; and 
(b) at least 1 of the following conditions applies:
!Is not a WOCBP (see definition in Section 10.4.3).
OR
!Is a WOCBP who agrees to use a highly effective contraceptive method (failure rate of <1% per year) with low user dependency during the intervention period and for at 
least [ADDRESS_1163264] dose of study intervention, which corresponds to the time needed to eliminate any reproductive safety risk of the study intervention(s). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 101OR
!Is a WOCBP and agrees to use a highly effective (failure rate of <1% per year) user-
dependent method of contraception during the intervention period and for at least [ADDRESS_1163265] dose of study intervention, which corresponds to the time needed to 
eliminate any reproductive safety risk of the study intervention(s). In addition to her use of the highly effective method above, she agrees to concurrently use an effective 
barrier method. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
The investigator is responsible for reviewing the woman’s medical history, menstrual history,and recent sexual activity in order to decrease the risk of enrolling a woman with an early, undetected pregnancy. 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, additional evaluation should be considered.
Women in the following categories are not considered WOCBP:
1. Premenopausal female with 1 of the following:
!Documented hysterectomy;
!Documented bilateral salpi[INVESTIGATOR_1656];
!Documented bilateral oophorectomy.
For individuals with permanent infertility due to a medical cause other than the above (eg, 
mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history interview. The method of documentation should be recorded in the participant’s medical record for the study.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 1022. Postmenopausal female:
!A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. In addition:
!A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal contraception or HRT. 
!A female on HRT and whose menopausal status is in doubt will be required to use one of the highly effective nonestrogen hormonal contraception methods if shewishes to continue her HRT during the study. Otherwise, she must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
10.4.4. Contraception Methods
Contraceptive use by [CONTACT_22856]/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
The following contraceptive methods are appropriate for this study:Highly Effective Methods That Have Low User Dependency 
1. Implantable progestogen-only hormone contraception associated with inhibition of 
ovulation.
2. Intrauterine device.3. Intrauterine hormone-releasing system.4. Bilateral tubal occlusion.5. Vasectomized partner.
!Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.
Highly Effective Methods That Are User Dependent 
6. Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation:
!Oral + barrier *
!Intravaginal + barrier *090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 103!Transdermal + barrier*
7. Progestogen-only hormone contraception associated with inhibition of ovulation:
!Oral + barrier*
!Injectable + barrier*
8. Sexual Abstinence
Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
* Acceptable barrier methods to be used concomitantly with options 6 or 7 for the study include any of the following:
!Male or female condom with or without spermicide;
!Cervical cap, diaphragm, or sponge with spermicide;
!A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods).090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page [ZIP_CODE].5. Appendix 5: Genetics
Use/Analysis of DNA
!Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Therefore, where local regulations and IRBs/ECs allow, a blood sample will be collected for DNA analysis.
!The scope of the genetic research may be narrow (eg, 1 or more candidate genes) or broad (eg, the entire genome), as appropriate to the scientific question under investigation.
!The samples may be analyzed as part of a multi-study assessment of genetic factors involved in the response to study intervention or study interventions of this class to understand treatments for the disease(s) under study or the disease(s) themselves.
!The results of genetic analyses may be reported in the CSR or in a separate study summary, or may be used for internal decision making without being included in a study report.
!The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality. 
!The samples will be retained as indicated:
!Retained samples will be stored indefinitely or for another period as per local 
requirements.
!Participants may withdraw their consent for the storage and/or use of their Retained Research Samples at any time by [CONTACT_7328] a request to the investigator; in this case, any remaining material will be destroyed. Data already generated from the samples will be retained to protect the integrity of existing analyses.
!Samples for genetic research will be labeled with a code. The key between the code and the participant’s personally identifying information (eg, name, address) will be held securely at the study site. 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page [ZIP_CODE].6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments and 
Study Intervention Rechallenge Guidelines
Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury but adapt are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a more serious potential outcome. These participants fail to adapt and therefore are “susceptible” to progressive and serious liver injury, commonly referred to as DILI. Participants who experience a transaminase elevation above 3 × ULN should be monitored more frequently to determine if they are “adaptors” or are “susceptible.”
In the majority of DILI cases, elevations in AST and/or ALT precede T bili elevations (>2 × 
ULN) by [CONTACT_22857]. The increase in T bili typi[INVESTIGATOR_161651]/ALT is/are 
still elevated above 3 × ULN (ie, AST/ALT and T bili values will be elevated within the same laboratory sample). In rare instances, by [CONTACT_29623] T bili elevations are detected, AST/ALT values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to T bili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered important medical events, even before all other possible causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:
!Participants with AST/ALT and T bili baseline values within the normal range who subsequently present with AST OR ALT values ≥3 × ULN AND a T bili value 
≥2 × ULN with no evidence of hemolysis and an alkaline phosphatase value 
<2 × ULN or not available.
!For participants with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, depending on which values are above the ULN at baseline:
!Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values ≥ 2 times the baseline values AND ≥3 
×ULN; or ≥ 8×ULN (whichever is 
smaller).
!Preexisting values of T bili above the normal range: T bili level increased from baseline value by [CONTACT_219911] ≥1 × ULN orif the value reaches ≥3 × ULN 
(whichever is smaller).090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 106Rises in AST/ALT and T bili separated by [CONTACT_726] a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferably within [ADDRESS_1163266] and ALT and T bili for suspected Hy’s law
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial abnormalities to determine etiology. A detailed history, including relevant information, such as review of ethanol, acetaminophen/paracetamol (either by [CONTACT_20025] a coformulated product in prescription or over-the-counter medications), recreational drug, or supplement (herbal) use and consumption, family history, sexual history, travel history, history of contact [CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected. Further testing for acute hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary tract), and collection of serum samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
T bili elevation defined above should be considered potential DILI (Hy’s law) cases if no other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page [ZIP_CODE].7. Appendix 7: Kidney Safety Monitoring Guidelines
10.7.1. Laboratory Assessment of Change in Kidney Function and Detection of Kidney 
Injury
Standard kidney safety monitoring requires assessment of baseline and postbaseline serum 
creatinine (Scr measurement to eGFR [Scr-based eGFR] or [eCrCl]). Baseline and postbaseline Scys makes it feasible to distinguish AKI from other causes of Scr increase. If Scr increase is confirmed after baseline, then reflex measurement of Scys is indicated to estimate the combined Scr-Scys eGFR calculation (for adults only).
Regardless of whether kidney function monitoring tests are required as a routine safety 
monitoring procedure in the study, if the investigator or sponsor deems it necessary to further assess kidney safety and quantify kidney function, then these test results should be managed and followed per standard of care.
10.7.2. Age-Specific Kidney Function Calculation Recommendations
[IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD-EPI [INVESTIGATOR_185560]
2021 CKD-
EPI          
[INVESTIGATOR_185571]
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤ 0.7 N/A eGFR = 143 × (Scr/0.7)-0.241  ×  (0.9938)Age
Female if > 0.7 N/A eGFR = 143 × (Scr/0.7)-1.200  ×  (0.9938)Age
Male if ≤ 0.9 N/A eGFR = 142 × (Scr/0.9)-0.302  ×  (0.9938)Age
Male if > 0.9 N/A eGFR = 142 × (Scr/0.9)-1.200  ×  (0.9938)Age
2021 CKD-
EPI          
[INVESTIGATOR_185572]-Scys 
CombinedScr
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤ 0.7 if ≤ 0.8 eGFR = 130 × (Scr/0.7)-0.219  × (Scys/0.8)-0.323  × (0.9961)Age
Female if ≤ 0.7 if > 0.8 eGFR = 130 × (Scr/0.7)-0.219  × (Scys/0.8)-0.778  × (0.9961)Age
Female if > 0.7 if ≤ 0.8 eGFR = 130 × (Scr/0.7)-0.544  × (Scys/0.8)-0.323  × (0.9961)Age
Female if > 0.7 if > 0.8 eGFR = 130 × (Scr/0.7)-0.544  × (Scys/0.8)-0.778  × (0.9961)Age
Male if ≤ 0.9 if ≤ 0.8 eGFR = 135 × (Scr/0.9)-0.144  × (Scys/0.8)-0.323  × (0.9961)Age
Male if ≤ 0.9 if > 0.8 eGFR = 135 × (Scr/0.9)-0.144  × (Scys/0.8)-0.778  × (0.9961)Age
Male if > 0.9 if ≤ 0.8 eGFR = 135 × (Scr/0.9)-0.544  ×  (Scys/0.8)-0.323  × (0.9961)Age
Male if > 0.9 if > 0.8 eGFR = 135 × (Scr/0.9)-0.544  ×  (Scys/0.8)-0.778  × (0.9961)Age
Inker LA et al. N Engl J Med. 2021;385:1737-49.16
10.7.3. Adverse Event Grading for Kidney Safety Laboratory AbnormalitiesAE grading for decline in kidney function (ie, eGFR or eCrCl) will be according to KDIGO
criteria. 090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page [ZIP_CODE].8. Appendix 8: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as AEs
!Marked sinus bradycardia (rate <40 bpm) lasting minutes.
!New PR interval prolongation >280 ms.
!New prolongation of QTcF to >480 ms (absolute) or by ≥60 ms from baseline.
!New-onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate <120 bpm.
!New-onset type I second-degree (Wenckebach) AV block of >30 seconds’duration.
!Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive ventricular complexes.
ECG Findings That May Qualify as SAEs
!QTcF prolongation >500 ms.
!New ST-T changes suggestive of myocardial ischemia.
!New-onset LBBB (QRS complex >120 ms).
!New-onset right bundle branch block (QRS complex >120 ms).
!Symptomatic bradycardia.
!Asystole:
!In awake, symptom-free participants in sinus rhythm, with documented periods 
of asystole ≥3.0 seconds or any escape rate <40 bpm, or with an escape 
rhythm that is below the AV node; 
!In awake, symptom-free participants with atrial fibrillation and bradycardia 
with [ADDRESS_1163267] 5 seconds or longer; 
!Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate >120 bpm.
!Sustained supraventricular tachycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 109!Ventricular rhythms >30 seconds’ duration, including idioventricular rhythm 
(HR <40 bpm), accelerated idioventricular rhythm (HR 40 bpm to <100 bpm),and monomorphic/polymorphic ventricular tachycardia (HR >100 bpm [such astorsades de pointes]).
!Type II second-degree (Mobitz II) AV block.
!Complete (third-degree) heart block.
ECG Findings That Qualify as SAEs
!Change in pattern suggestive of new myocardial infarction.
!Sustained ventricular tachyarrhythmias (>30 seconds’ duration).
!Second- or third-degree AV block requiring pacemaker placement.
!Asystolic pauses requiring pacemaker placement.
!Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
!Ventricular fibrillation/flutter.
!At the discretion of the investigator, any arrhythmia classified as an adverse experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and [COMPANY_007] study team, and not to be considered as all-inclusive of what to be reported as AEs/SAEs.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page [ZIP_CODE].9. Appendix 9: Prohibited Concomitant Medications That May Result in DDI
The prohibited concomitant medications listed below should not be taken with PF-[ADDRESS_1163268] of drugs prohibited for potential DDI concerns with the IMP may be revised during
the course of the study with written notification from sponsor, to include or exclude specific drugs or drug categories for various reasons (eg, emerging DDI results for the IMP, availability of new information in literature on the DDI potential of other drugs).
This is not an all-inclusive list. Site staff should consult with the sponsor or designee with any questions regarding potential DDI.
P-gp Substrates Moderate to Strong 
CYP3A InhibitorModerate to Strong CYP3A inducer
digoxin amprenavir apalutamide
dabigatran amiodarone asunaprevir and beclabuvir and daclatasvir
aprepi[INVESTIGATOR_837526] (dipyrone)
diltiazem mitapi[INVESTIGATOR_837527]090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 111P-gp Substrates Moderate to Strong 
CYP3A InhibitorModerate to Strong CYP3A inducer
fluconazole phenytoin
grapefruit juice rifabutin
grapefruit juice - double strength rifampin
idelalisib rifapentine
imatinib semagacestat
indinavir sotorasib
indinavir and ritonavir St. John's wort (Hypericum perforatum)
ipatasertib talviraline
isavuconazole telotristat ethyl
istradefylline thioridazine
itraconazole tipranavir and ritonavir
josamycin
ketoconazole
lefamulin
letermovir
lonafarnib
lopi[INVESTIGATOR_837528]-[ADDRESS_1163269] label for any other medication used during the study 
for information regarding medication that is prohibited for concomitant use.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page [ZIP_CODE].10. Appendix 10: Signs and Symptoms Attributable to COVID-19
Table 5. Signs and Symptoms Attributable to COVID-19
Daily Sign and Symptom Collection13Entry Criterion #4
Targeted (used for 
study entry)Daily Signs and 
Symptom Collection
Stuffy or runny nose X X
Sore throat X X
Cough X X
Feeling hot or feverish X X
Fatigue (low energy or tiredness) X X
Shortness of breath or difficulty breathing X X
Shortness of breath (difficulty breathing) while restingX
Shortness of breath (difficulty breathing) while physically activeX
Chest pain X
Low energy or tiredness after physical activity X
Difficulty concentrating X
Chills or shivering X X
Muscle or body aches X X
Diarrhea (loose or watery stools) X X
Nausea (feeling like you wanted to throw up) X X
Vomiting (throw up) X X
Headache X X
Loss of smell X
Loss of taste X
Sustained alleviation of all targeted signs and symptoms is defined as the event occurring on 
the first of 4 consecutive days when all symptoms scored as moderate or severe at study entry are scored as mild or absent AND all symptoms scored mild or absent at study entry are scored as absent. Missing severity at baseline will be treated as mild.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 113The decision to require 4 consecutive days with all targeted symptoms absent or alleviated
was based on exploratory analyses of data from the ACTIV-2/A5401 study which suggestedthat this choice (rather than requiring fewer consecutive days) better captured sustainedsymptom resolution with low probability of subsequent relapse. The outcome measurerequires 4 consecutive days of targeted symptoms being reported as alleviated or resolved. This definition may be updated based on regulatory feedback/interactions and will be described in the SAP.
Sustained resolution of all targeted signs and symptoms is defined as the event occurring on 
the first of 4 consecutive days when any symptoms scored as absent, mild, moderate or severe at study entry are scored as absent.
Progression to a worsening status for any targeted symptom will be derived 
programmatically based upon increasing severity (ie, the first time any targeted symptom worsens after treatment relative to baseline):
Progression to worsening (Yes/No)
Increasing severity Yes
Not increasing severity No
Symptom recurrence will be assessed using 2 different definitions:
1. Sponsor definition: Any improvement in targeted COVID-19 signs and symptoms 
that subsequently worsened (total symptom score increased by ≥4).
2. FDA definition: After achieving short symptom recovery (the first day of at least two 
consecutive diary entries where all targeted symptoms are absent), symptom rebound is the first day of at least two consecutive diary entries after Day 5 where there is any targeted symptom (regardless of severity), or when a subject is hospi[INVESTIGATOR_837529].090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page [ZIP_CODE].11. Appendix 11: Definition of Viral RNA Rebound
Viral RNA rebound will be assessed using the following FDA-based definition, based upon 
the FDA analysis of the ADMC and ADSL datasets from NDA 217188. This approach accounts for the impact of antiviral therapy on early viral RNA decline.
Within the population of Day 5 virologic responders (Day 5 VL <LLOQ or
≥1l o g
10copi[INVESTIGATOR_014]/mL decline from baseline to Day 5), virologic rebound is defined as:
1) Day 5 VL <LLOQ AND at Day 10, 14, or 21 VL ≥LLOQ;
OR
2) Day 5 RNA ≥LLOQ AND Day 10, 14, or 21 RNA ≥0.5 log 10copi[INVESTIGATOR_014]/mL increase 
from Day 5.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page [ZIP_CODE].12. Appendix 12: Protocol Amendment History
The protocol amendment summary of changes table for the current amendment is located 
directly before the TOC. The protocol amendment summary of changes tables for past amendment(s) can be found below:
Amendment 1 (24 March 2023)Overall Rationale for the Amendment: To update prohibited concomitant medications in 
line with emerging PK data and incorporate regulatory feedback.
Description of Change Brief Rationale Section # and Name
[CONTACT_185628](s)
Addition of PK data from 
PART-5: DDI (midazolam) of Study C5091001.To update the Clinical Overview with emerging PK data.Section 2.2.2. Clinical Overview
Deletion of text prohibiting use of medications highly dependent on CYP3A4 for clearance with narrow TI during study.PF-[ADDRESS_1163270] CYP3A4 perpetrator risk.Appendix 4
Addition of inclusion criterion #5, addition of new exclusion criterion #2, revision of exclusion criterion #11 and clarification of therapy permitted and prohibited during the study.To address comments received from the FDA.Section 1.1 Synopsis, Section 5.1 Inclusion Criteria, Section 5.2 Exclusion Criteria, Section 6.9 Prior and Concomitant Therapy and Section 7.1 Discontinuation of Study Intervention
Addition of assessments for viral RNA rebound and symptom recurrence as exploratory objectives and endpoints in Section 3. Corresponding addition of definitions for symptom recurrence to Appendix 10 To address comments received from the FDA.Section 3 Objectives, Endpoints, and Estimands, Section 10.10 Appendix 10 Signs and Symptoms Attributable to COVID-19 and Section 10.11 Appendix 11 Definitions of Viral RNA Rebound.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 116Description of Change Brief Rationale Section # and Name
[CONTACT_837560] 11.
Addition of SARS-CoV-2 RNA level assessments at Day 21 and Day 33, with corresponding edit of Day 21 visit from “T” to “S/P” and Day 33 visit from “T” to “S/P/T”.To address comments received from the FDA.Section 1.3 SoA SARS-CoV-2 RNA level assessment (NP) and Study Visit Location
Addition of targeted physical exam and vital signs assessment at Day 21 site visit and Day 33 visit if participant is still symptomatic.To address comments received from the FDA.Section 1.3 SoA Targeted physical examination and Vital signs
Addition of instructions to sites for collecting unscheduled NP samples in the case of symptom worsening or recurrence.To address comments received from the FDA.Section 8.7.5 Viral RNA Level Assessments
Addition of a PK sample by [CONTACT_837556]-sampling before administration of second dose of PF-07817883.To address comments received from the FDA.Section 1.3 SoA PK micro-sampling 
Addition of optional Day 21 assessment.To address comments received from the FDA.Section 1.3 SoA Retained research samples for biomarkers (Prep B2.5, prep R1)
Addition of AE assessments at Days 2 and 4.AEs will be assessed if optional Day 2 and 4 visits occur.Section 1.3 SoA Serious and nonserious AE monitoring
Removed need for participant to check temperature.Fever will be captured as part of the daily signs and symptoms collection through the “feeling hot or feverish” symptom. To avoid duplication of data, the participant will not measure their temperature.Section 8.2.3 Daily Signs and Symptoms of COVID-19 and Section [IP_ADDRESS] At-Home Devices for Vital Signs.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 117Description of Change Brief Rationale Section # and Name
[CONTACT_837561]. Removedcorrelating footnote.Fever will be captured as part of the daily signs and symptoms collection through the “feeling hot or feverish” symptom. To avoid duplication of data, the participant will not measure their temperature.Section 10.10 Appendix 10 Signs and Symptoms Attributable to COVID-19
Removed need for participants to be supplied with a pulse oximeter.Oxygen saturation will be checked during all in-person site visits.Section 8.3.4. Vital Signs and Section [IP_ADDRESS] At-Home Devices for Vital Signs
Addition of eGFR(combined Scr+Scys) and albumin assessments and edits to collect cystatin C post-baseline at each lab assessment.Updates to kidney function assessments as per guidance from [COMPANY_007] Kidney Safety Council recommendation.Section 10.2 Appendix 2 Clinical Laboratory Tests
Nonsubstantial Modification(s)
Added text from Exclusion Criterion #15 into Section 1.3 SoA Notes for Safety Laboratory Assessments row.Clarification of this text is to provide guidance surrounding laboratory assessments.Section 1.3 SoA Safety Laboratory Assessments
Edited “Study Visit Location” for Day 2 and 4 optional visits from “NA” to “T”.Clarification that these optional visits may be conducted by [CONTACT_223938].Section 1.3 SoA Study Visit Location
Addition of “Day 1” to the SoA Notes column.Clarification that post-dose ECGs should be performed within [ADDRESS_1163271]-dose on Day 1.Section 1.3 SoA 12-lead ECG
Edited “NP” to “nasal”. Clarification that a nasal 
sample is required for the selected RAT kit used at screening.Section 1.1 Synopsis, Section 1.3 SoA, Section 5.1 Inclusion Criteria and Section 8.7.1 Rapid Antigen Assessments
Deletion of “predicted" and  “preliminary” for toxicity margin text and edit “total” to “unbound” for C
maxand 
AUC 24values.Clarification edits to align with Investigators Brochure Version 2 updates.Section 2.2.1 Nonclinical Studies of PF-07817883090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 118Description of Change Brief Rationale Section # and Name
[CONTACT_837562]/PD modeling and simulation results.Clarification that PK/PD modeling and simulation results would only impact dose selection decisions at a program level and not the protocol level [ie, current study]).Section 9.6.1 Early PK/PD Unblinding Plan
Addition of sponsor’s address.To comply with new regulatory requirements.Title page
Edits throughout Section 10.[ADDRESS_1163272] inadvertent errors.Several sections throughout090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page [ZIP_CODE].13. Appendix 13: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
%CV percent coefficient of variation
μM micromolar
3CL 3C-like
Abs absolute
AE adverse event
AKI acute kidney injury
ALT alanine aminotransferase
ARDS acute respi[INVESTIGATOR_837530] 24 area under the concentration-time curve from time zero to 24 hours 
(1d ay)
AV atrioventricular
AxMP auxiliary medicinal product
∀-hCG ∀-human chorionic gonadotropin
BID twice daily
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CAR chimeric antigen receptor
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD-EPI [INVESTIGATOR_837531] r renal clearance
Cmax maximum observed concentration
CO2bicarbonate
CONSORT Consolidated Standards of Reporting Trials
COVID-[ADDRESS_1163273] research organization
CSR Clinical Study Report090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )CCI
CCI
CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 120Abbreviation Term
CT clinical trial
CTIS Clinical Trial Information System
Ctrough drug concentration observed at the last planned timepoint prior to
dosing
CYP cytochrome P450
CYP3A4 cytochrome P450 3A4
DAIDS Division of AIDS
DCT data collection tool
DDI drug-drug interaction 
DICI drug-induced creatinine increase
DIKI drug-induced kidney injury
DILI drug-induced liver injury
difTarget difference in response between the highest dose (600 mg q12h) and 
placebo
dNHBE differentiated normal human bronchial epi[INVESTIGATOR_837532]
E1 primary analysis estimand
E2 estimand for supplementary analyses
EC ethics committee
EC 50 drug concentration at which 50% inhibition of viral replication isobserved; concentration required for 50% effect
EC 90 drug concentration at which 90% inhibition of viral replication is
observed; concentration required for 90% effect
ECC emergency contact [CONTACT_837557] 
(European Clinical Trials Database)
FAS full analysis set
FDA Food and Drug Administration090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 121Abbreviation Term
FE food effect
FIH first-in-human
FSH follicle-stimulating hormone
fu fraction unbound
F/U follow-up
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
HCoV human coronavirus
HCP healthcare provider
HCT hematopoietic cell transplantation
HIV human immunodeficiency virus
hr hour
HR heart rate
HRT hormone replacement therapy
hs-CRP high-sensitivity C-reactive protein
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use
ICU intensive care unit
ID identification
IgG immunoglobulin G
IgM immunoglobulin M
IMP investigational medicinal product
IND Investigational New Drug
INR international normalized ratio
IP investigational product
IPAL Investigational Product Accountability Log
IPM investigational product manual
IRB Institutional Review Board
IRC internal review committee
IRT Interactive Response Technology
IV intravenous
KDIGO Kidney Disease: Improving Global Outcomes
KO knock out
LBBB left bundle branch block
LDH lactate dehydrogenase
LFT liver function test
LLOQ lower limit of quantitation
LS least-squares
mAb monoclonal antibody
MAD multiple ascending dose090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )CCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 122Abbreviation Term
ME metabolism and excretion
MERS Middle East Respi[INVESTIGATOR_837533]/mL milli-international units per millilite r
mL millilite r
mm3millimeter cubed
MMRM mixed model for repeated measures
MOA mechanism of action
Mpromain protease
MQI medically qualified individual
ms milliseconds
MTD maximum tolerated dose
NA not applicable
NDA New Dru g Application
NIMP noninvestigational m edicinal product
NOAEL no observed adverse effect level
NP nasopharyngeal
NR not reportable
PD pharmacodynamic(s)
P-gp p-glycoprotein
PI [INVESTIGATOR_19959](s)
PR pulse rate
PRO patient reported outcomes
PSSA [COMPANY_007]'s Serious Adverse Event Submission Assistant
PT prothrombin time
PVC premature ventricular contraction
q12h every 12 hours
QTc corrected QT interval
QTcF QTc corrected using Fridericia’s formula
QTL quality tolerance limit
qual qualitative
RAT rapid antigen testing
rBA relative bioavailability
RBC red blood cell
RNA ribonucleic acid
RT-PCR reverse transcriptase– polymerase chain reaction
[S] investigational site
SAD single ascending dose
SAE serious adverse event090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
CCICCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 123Abbreviation Term
SAP Statistical Analysis Plan
SARS-CoV-[ADDRESS_1163274] operating procedure
SRSD Single Reference Safety Document
S[LOCATION_003]R Suspected Unex pected Serious Adverse Reaction
[T] telehealth visit
Tbili total bilirubin
TEAE treatment-emer gent adverse event
TMPRSS2 transmembrane serine protease [ADDRESS_1163275] infection
VeroE6 monkey kidney cells E6
VL viral load
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potential090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
CCICCI
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page [ZIP_CODE]. REFERENCES
1. World Health Organization.  WHO Situation Report 51 Coronavirus disease 2019
(COVID-19). 11 March 2020. Available from: https://www.who.int/docs/default-
source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10. Accessed on: 19 Jan 2023.
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA.2020;323(13):1239-42.
3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
Comorbidities, and Outcomes Among 5700 Patients Hospi[INVESTIGATOR_45086]-19 inthe [LOCATION_001] City Area. JAMA. 2020;323(20):2052-59.
4. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 [LOCATION_006] patients in
hospi[INVESTIGATOR_103182]-19 using the ISARIC WHO Clinical Characterisation Protocol:prospective observational cohort study. BMJ. 2020;369:m1985.
5. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospi[INVESTIGATOR_45077]
2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.2020;323(11):1061-69.
6. Pei G, Zhang Z, Peng J, et al. Renal Involvement and Early Prognosis in Patients with
COVID-19 Pneumonia. J Am Soc Nephrol. 2020;31(6):1157-65.
7. Nopp S, Moik F, Jilma B, et al. Risk of venous thromboembolism in patients with
COVID-19: A systematic review and meta-analysis. Research and practice inthrombosis and haemostasis. 2020;4(7):1178-91.
8. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospi[INVESTIGATOR_837534] 5279 people with coronavirus disease 2019 in [LOCATION_001] City:prospective cohort study. BMJ. 2020;369:m1966.
9. Reilev M, Kristensen KB, Pottegard A, et al. Characteristics and predictors of
hospi[INVESTIGATOR_837535] [ADDRESS_1163276] forSARS-CoV-2 in Denmark: a nationwide cohort. Int J Epi[INVESTIGATOR_5541]. 2020;49(5):1468-81.
10. Centers for Medicare & Medicaid Services. (2023).  COVID-19 Monoclonal
Antibodies. 2023. Available from: https://www.cms.gov/monoclonal.
11. NIH COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19)
Treatment Guidelines as of January 2023. Available from:https://www.covid19treatmentguidelines.nih.gov/. Accessed on: 03 Jan 2023.
12. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular
filtration rate. Ann Intern Med. 2009;150(9):604-12.
13. US Food and Drug Administration. Assessing COVID-19-Related Symptoms in
Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and BiologicalProducts for COVID-19 Prevention or Treatment. September 2020. Available from:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs. Accessed on: 30 Jan 2023.
14. U.S. Department of Health and Human Services NIoH, National Institute of Allergy
and Infectious Diseases, Division of AIDS,. Division of AIDS (DAIDS) Table forGrading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )
PF-07817883
Protocol C5091003Final Protocol Amendment 2, 14 April 2023
PFIZER CONFIDENTIAL 
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (01 March 2021)
Page 125July 2017. Available from: 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Accessed on: 10 Jun 2021.
15. NIH US National Library of Medicine. (2022).  Study [STUDY_ID_REMOVED]: EPIC-HR:
Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospi[INVESTIGATOR_837536]-19. Available from:https://www.clinicaltrials.gov/ct2/history/[STUDY_ID_REMOVED]?V_21&embedded=true.
16. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based
Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-49.
17. Deo R, Choudhary MC, Moser C, et al. Symptom and Viral Rebound in Untreated
SARS-CoV-2 Infection. Ann Intern Med. 2023;10.7326/M22-2381.090177e19d31d7d8\A pproved\A pproved On: 14-A pr-2023 20:32 (GMT )